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Abstract 
A novel immuno-stimulatory polysaccharide-protein complex (ISPP-Rb) was isolated from 
Royoporus badius sporocarps, collected in northern BC forests. ISPP-Rb was purified from the 
water extract of R. badius using anion-exchange and size-exclusion chromatography and could 
significantly activate murine macrophage (RAW 264.7) cells. ISPP-Rb is highly branched and has 
an average molecular weight of 400 kDa. GC-MS data suggest the polysaccharide component of 
ISPP-Rb has a backbone of (1 → 6)-Gal/Man and (1 → 2,6)-Glc, with the latter being attached to 
either glucose, galactose or fucose at its terminal end. The protein component, found to be 
indispensable for its immuno-stimulatory activity, is proposed to link to a mannose residue via O-
linked glycosylation. ISPP-Rb was able to induce various proinflammatory cytokines including 
TNF-α, IP-10, MIP-2, G-CSF, GM-CSF, MIP-1α, and MIP-1β. This is the first immuno-
stimulatory compound to be reported from R. badius, and hence making ISPP-Rb novel. 
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Chapter 1 
Introduction and Literature Review 
 This chapter will mainly describe (i) a brief history of cancer and how the disease has 
emerged as a major health concern in recent years, (ii) the importance and value of mushrooms as 
anti-cancer agents, (iii) the biological activity of some North American mushrooms (iv) a short 
overview on the mushroom under investigation (Royoporus badius), (v) the use of large molecules 
from natural sources as an alternative for anti-cancer drugs, (vi) the re-emergence of natural 
products, and (vii) the experimental objectives of this research. 
1.1 Cancer and Its Properties 
The word “cancer” was first described by Hippocrates, the father of medicine using the 
Greek word Karkinos, which means tumors (Nobili et al., 2009). However, cancer was believed 
to have been documented even earlier, during the classical periods of the Egyptian Pharaohs’ reign 
(Nobili et al., 2009). Cancer is a deadly disease involving the formation of malignant tumors as a 
result of uncontrolled cell growth and their ability to invade or metastasize to other regions of the 
body (Dai et al., 2016). Such a phenomenon is thought to be caused by several factors including 
exposure to carcinogens, radiation, and viruses, along with genetic inheritance (Sudhakar, 2009). 
It is believed that a vast majority of cancer cells possess six immortal traits; the ability (a) to bypass 
cell death (apoptosis), (b) to be self-sustaining in growth signals, (c) to be unresponsive to anti-
proliferative signals, (d) to metastasize, (e) to form new blood vessels (angiogenesis) sustainably, 
and (f) to replicate endlessly, allowing them to breach the anti-cancer defense mechanism of 
cellular tissues (Hanahan & Weinberg, 2000). Today, cancer is documented as a leading cause of 
deaths globally regardless of  economic status, and the numbers are estimated to rise even further 
due to population growth, age, and the adoption of unhealthy lifestyles (Torre et al., 2016). There 
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were 14.1 million new cancer cases followed by 8.2 million deaths from the disease worldwide in 
2012, whereby lung, breast and colorectal cancer topped the list as the most commonly diagnosed 
cancers; while lung, liver and stomach cancer were the most prevalent cause of cancer death cases 
(Ferlay et al., 2014). Interestingly, despite numerous research efforts in search of a cure, cancer 
remains as one of the leading causes of deaths in the world. 
Although there are conventional methods such as chemotherapy, radiotherapy and surgery 
to treat cancer, these options often come with limitations and drawbacks (Safarzadeh et al., 2014). 
Among the downsides of the aforementioned treatments are: (i) patients diagnosed with cancer at 
a late stage are unable to undergo surgery; (ii) a short postoperative survival rate of not more than 
five years along with a risk of reoccurrence for most cancer patients; (iii) the harmful side effects 
from chemotherapy and radiotherapy despite it being an efficient treatment option; and (iv) the 
high resistance and insensitivity of some cancers to both chemotherapy and radiotherapy, 
rendering the treatment ineffective (Qi et al., 2010). In another report by Chakraborty & Rahman 
(2012), they described numerous reasons behind the challenges faced in treating cancer, such as 
troubles targeting cancer stem cells, anti-cancer drug resistant cancer cells, asymptomatic cancer 
progression, limited number of cancer epigenetic profiling followed by low specificity of current 
existing epi-drugs, poor diagnosis and prognosis due to lack of effective cancer biomarkers, the 
limitation of chemotherapeutic agents due to cytotoxic effects, and the metastatic nature of cancer 
cells. 
The use of anti-cancer drugs in chemotherapy, as previously mentioned, often results in 
much unwanted side effects due to its high toxicity. For instance, in spite of the remarkable potency 
of platinum-based Cisplatin in cancer treatment, the use of the drug results in an extensive level of 
cytotoxicity as Cisplatin often interferes with the DNA replication and/or transcription mechanism 
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and disrupts biochemical reactions and pathways by binding to enzymes, leading to issues 
involving nervous and renal system toxicity, along with bone marrow suppression, with 
combinational chemotherapy using Cisplatin being linked to the resistance to the drug itself  
(Florea & Büsselberg, 2011). Another side effect, the most commonly observed in chemotherapy 
is hair loss (alopecia). Alopecia can be classified into (i) telogen effluvium, a condition involving 
no more than 50% hair loss as a result of the use of 5-fluorouracil, methotrexate, and retinoids 
during 3-4 months of chemotherapy, and (ii) anagen effluvium, a situation where significant to 
complete hair loss occurs 1-2 months post-treatment with chemotherapeutic agents like 
cyclophosphamide, etoposide, topotecan, and paclitaxel (Yeager & Olsen, 2011). In addition to 
that, Docetaxel, an anti-cancer drug used to treat nonsmall cell lung cancers has been reported to 
induce fluid retention leading to several pulmonary complications not only in single drug 
chemotherapy, but also with combinational chemotherapy or radiotherapy (De Sanctis et al., 2011). 
According to Remesh, (2012), oral toxicity involving the use of anti-cancer chemotherapeutic 
drugs is also a common side effect. Drugs like Dactinomycin and Doxorubicin causes damage to 
the buccal or orolabial mucosa due to the cytotoxic effects slows down the cells’ renewal rate, 
making it susceptible to various infections including stomatitis. The above described drugs are just 
a few of the many examples of chemotherapeutic anti-cancer agents that can result in 
complications during cancer treatments, hence limiting their efficacy. Therefore, many have 
directed their focus towards a more natural approach, i.e. the use of natural products. 
The use of animal-, plant-, microorganism- and marine-based natural products as medicines 
to treat diseases have dated back to ancient times (Yuan et al., 2016). Today, at least 60% of the 
anti-cancer drugs approved and clinically used are derived from natural products, as manipulation 
of the bioactive compounds can be performed through structural modification or transformation, 
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leading to production of a more potent, yet less toxic derivative (Song et al., 2014). Furthermore, 
Woosley & Cossman (2007) claimed that despite the long duration, immense effort and huge 
monetary investment made into drug research and development, only 10% of the drugs that enter 
clinical testing by the Food and Drug Administration (FDA) will be deemed safe and qualified for 
public use. Taken together, it is therefore understandable that researchers have re-focused on 
discovering novel anti-cancer compounds from natural sources. 
With the increasing number of cancer cases globally, people are starting to show interest 
in a healthier approach, cancer chemoprevention, which is cheaper and safer compared to that of 
the cancer treatment (Gullett et al., 2010). This preventive approach involves the long-term 
administration of either synthetic, natural or biological agents by patients to decrease or delay the 
occurrence or process of tumor formation, with early success shown  in trials involving breast, 
colon and prostate cancer (Steward & Brown, 2013). According to Gullett et al. (2010), the 
simplest way to practice chemoprevention is by consuming a diet that consists of a wide variety 
of foods. Green plants have benefited mankind for a very long time by serving as a source of 
medicine and traditional remedies, while fungi were often overshadowed (Chatterjee et al., 2011). 
However, fungi, especially mushrooms are currently attracting interest worldwide and are 
expected to contribute enormously to the nutraceutical and pharmaceutical industry in the near 
future, mainly due to their antineoplastic (tumor inhibition) properties, with mushroom-derived 
immunostimulants and adaptogens serving as key anti-cancer agents for clinical purposes 
(Chatterjee et al., 2011). Hence, this provides a platform to further pursue the exploration of 
mushroom metabolites in search for potential anti-cancer compounds. 
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1.2 Medicinal Mushrooms and Their Role in Treating Cancer 
 The historic use of mushrooms as traditional medicine originated in the far east, and is 
currently attracting a lot of interest worldwide as mushroom metabolites (organic compounds not 
directly involved for growth, development and reproduction of the organism) are deemed safe and 
can be incorporated into our diet without the need to undergo lengthy clinical trials (Lull et al. 
2005; Seca & Pinto, 2018). The potential of  mushrooms as therapeutics is huge, with many known 
to exhibit myriad biological activities such as anti-cancer, anti-diabetic, anti-hypercholesterolemia, 
anti-hypertensive, anti-inflammatory, anti-microbial, antioxidant, immuno-modulatory, and liver-
protective activities (Zhang et al., 2016). Mushrooms have been used as food and medicines since 
ancient times (Wasser, 2014). It was documented that mushrooms were consumed by Greek 
warriors in belief that they act as an energy booster during battle, while mushrooms were highly 
treasured by Egyptian Pharaohs as a delicacy (Rahi & Malik, 2016). In addition, ancient Romans 
believed that mushrooms were the “Food of the Gods”, the Chinese worshipped mushrooms as the 
“elixir of life” for centuries, and the Japanese emperors highly valued the mushroom Lentinus 
edodes (Berk.) Pegler as an aphrodisiac (Chang & Buswell, 1996). According to Wani et al. (2010), 
in spite of the astonishing health benefits of mushrooms and their long history of medicinal use, it 
was not until the 1960s before the bioactivity of mushrooms was scientifically evaluated. 
 One of the pioneer scientific research studies conducted on mushroom bioactivity was by 
Ikekawa et al. (1969), where hot water extracts of seven different mushrooms were tested on 
tumor-bearing mice for anti-tumor activity, with all extracts showing tumor inhibition of over 40%, 
with subsequent purification of one of the mushrooms (L. edodes) exerting more than 95% tumor 
inhibition in vivo; the inhibitor compound was expected to be a polysaccharide. Today, countless 
research studies have been performed to evaluate the biological activity of mushrooms, and 
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according to Ivanova et al. (2014), the anti-cancer effect of mushrooms can be derived from (i) 
large molecules, which mainly comprises of polysaccharides, polysaccharide-protein complexes, 
proteins and dietary fibers, and (ii) small molecules, such as terpenoids, steroids, phenolics, and 
more.  
Chen et al. (2012) discovered a protein molecule called AAD with DNA cleaving activity. 
It was purified from Agrocybe aegerita (now known as Cyclocybe aegerita (V. Brig.) Vizzini), 
and the protein inhibited cell proliferation in liver, cervical and brain cancer cell lines through 
apoptosis as a result of chromatin condensation and sub-G1 cell cycle arrest in a caspase-dependent 
pathway. A 32 kDa lectin was isolated from the fruiting body of Russula lepida Fr. and was found 
to potently inhibit cell proliferation of two cancer cell lines, namely hepatoma (HepG2) cells and 
human breast cancer (MCF-7) cells with an IC50 of 1.6 μM and 0.9 μM respectively, and the 
growth-inhibitory property of the lectin was also in line with the reduction in tumor size when 
treated to mice containing S-180 tumor (Zhang et al., 2010). Furthermore, a water-soluble 
polysaccharide (ISP2A) purified from the fruiting body of Inonotus obliquus (Ach. ex Pers.) Pilát 
was reported to inhibit human gastric cancer cell line (SGC-7901) tumor-bearing nude mice in 
vivo but showed no significant activity in vitro, and was able to upregulated lymphocyte 
proliferation along with an increase in the TNF-α secretion in peritoneal macrophages (Fan et al., 
2012). Moreover, two water extracts of Cordyceps militaris (L.) Fr. exerted strong immuno-
stimulating activity by promoting the secretion of COX-2, IL-1β, and TNF-α in THP-1 
macrophage cells; while the alkaline extract of C. militaris demonstrated potent anti-inflammatory 
actions with the active compound being a (1 → 3)-β-D-glucan (Smiderle et al., 2014). 
As aforementioned, mushroom-derived small molecules were also found to possess anti-
cancer properties. Recently, three triterpenes from an ethyl acetate extract of king oyster 
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mushroom, Pleurotus eryngii (DC.) Quél, were shown to exhibit strong growth-inhibitory action 
against breast cancer (MCF-7) cell lines in vitro and some immuno-modulatory effects in mice. 
These compounds were successfully identified and their structures elucidated (Xue et al., 2015a; 
Xue et al., 2015b). Elsewhere, eight triterpenes were extracted from the fruiting bodies of Antrodia 
camphorata (M. Zhang & C.H. Su) Sheng H. Wu, with all eight exerting their cytotoxic effect in 
at least one cancer cell line, and three (zhankuic acids) out of the eight were found to induce cell 
apoptosis in two cancer cell lines, namely HT-29 and SW-480 cells by causing sub-G1 cell cycle 
arrest, without exhibiting any toxicity in normal non-cancer cell lines (Yeh et al., 2009). Other 
than that, an anti-cancer ergosterol molecule (ARHPLC-1) purified from Amauroderma rude 
(Berk.) Torrend extracts was reported to upregulate the expression of a tumor suppressor gene 
(FOXO3) in a breast cancer (MDA-MB-231) cell lines, causing an increase in the downstream 
cascade signaling events leading to cell apoptosis, and prolong the life span of B16 tumor-bearing 
mouse (Li et al., 2015). 
The above examples are just a few of the many studies describing anti-cancer properties of 
mushrooms, and the numbers will only increase as more mushrooms are tested. With so much 
literature citing their medicinal potential, it is clear that mushrooms would serve as a heightened 
platform for the discovery of a potential anti-cancer drug. 
1.3 Mushrooms and Their Bioactivity Profile in North America 
Mushrooms belong to the Kingdom Fungi, and are classified alongside with bracket fungi, 
chanterelles, club and coral fungi, puffballs, stinkhorns, toadstools, as well as plant-parasitic rusts 
and smuts in the Basidiomycota division (Rahi & Malik, 2016). According to Wasser (2014), there 
are approximately 150,000 – 160,000 mushroom species across the globe, and with an estimate of 
90% which have yet to be explored. Mushrooms have been used as a source of traditional medicine 
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in Asia for a very long period of time, however, this medicinal field is relatively new to countries 
in the West (Chatterjee et al., 2011).  
In Canada, other than the studies performed by Dr. Chow Lee’s research team at the 
University of Northern British Columbia (UNBC), only a few studies have been conducted on the 
bioactivity of mushrooms native to Canada. The first study involved the discovery of a small 
molecule, ganoderma aldehyde from Ganoderma applanatum (Pers.) Pat. collected in the forest of 
British Columbia, whereby the structure of the compound was elucidated with the aid of both one-
dimensional (1-D) and two-dimensional (2-D) Nuclear Magnetic Resonance (NMR) along with 
Mass Spectrometry (MS) analysis; however, the bioactivity of the compound isolated was not 
described (Ming et al. 2002). Later, Van et al. (2009) demonstrated that I. obliquus collected from 
Manitoba, exerted anti-inflammatory activity on RAW 264.7 macrophage cells by down-
regulating its production of both nitric oxide (NO) and several lipopolysaccharide-induced 
inflammatory cytokines, but with no further studies performed to identify and purify the bioactive 
compound. Elsewhere in the province of Quebec, a large β-glucan (CDP) with anti-inflammatory 
activity, with an estimated size of over 1 million Daltons was successfully purified from Collybia 
dryophila (now known as Gymnopus dryophilus (Bull.) Murrill), was shown to inhibit the 
production of nitric oxide in activated murine macrophage (RAW 264.7) cells (Pacheco-Sanchez 
et al., 2006). Interestingly, polysaccharides similar to CDP were also found in L. edodes and 19 
other mushrooms collected in Quebec (Pacheco-Sánchez et al., 2007). 
Recently, Dr. Lee’s research team at UNBC was the first to report the growth-inhibitory 
and immuno-modulatory activity of 12 mushrooms. This included five wild mushrooms collected 
from the forest of northern-central BC, namely Gyromitra esculenta (Pers.) Fr., Hericium 
coralloides (Scop.) Pers., Hydnellum sp., Leucocybe connata (Schumach.) Vizzini, P. Alvarado, 
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G. Moreno & Consiglio, and Trichaptum abietinum (Dicks.) Ryvarden, along with seven other 
well-known medicinal mushrooms (Smith et al., 2017). In addition, a growth-inhibitory 
polysaccharide (GIPinv) was successfully purified from Paxillus involutus (Batsch) Fr., a forest 
mushroom also found close to urban trees, which exerted potent growth-inhibitory activity against 
several cancer cell lines by inducing apoptosis in cancer cells (Barad et al., 2018). 
With such limited research done on the therapeutic activity of mushrooms in BC and 
elsewhere in Canada, combined with the high potential of mushrooms to serve as a pharmaceutical 
and nutraceutical hub, further studies on their bioactivity are therefore warranted. 
1.4 The Mushroom Royoporus badius (Pers.) A.B. De  
Royoporus badius is a fairly large polypore (up to 15 cm in width) with a dark central or 
lateral stipe and a slightly hairy base (Glaeser & Smith, 2010), which can be found distributed in 
Asia, Australia, Europe and North America (De et al., 1997). The mushroom had undergone 
several name changes, including Boletus badius (1801), Grifola badia (1821), Polyporus badius 
(1832), and Polyporellus badius (1989), before being recognized today as Royoporus badius in 
1997 (Razaq & Shahzad, 2016). R. badius is also commonly known as the Black-Footed Polypore 
(Doskocil et al., 2016). 
According to Zmitrovich & Kovalenko (2016), polyporoid and lentinoid fungi are 
important producers of substances having anti-hyperlipidemic, anti-tumoral, anti-viral, and 
immuno-modulatory effects. Currently, there are only two studies conducted to assess the 
biological activity of, R. badius sporocarps. Recently Doskocil et al. (2016) assessed the 
cytotoxicity and immuno-modulatory activity of R. badius, along with 26 other polypore species, 
with the results demonstrating that the ethanol extracts of R. badius had very minimal cytotoxicity 
towards two colorectal cancer cell lines, but exerted comparable immuno-stimulatory effects to 
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lipopolysaccharide (LPS) and their reference control (Ganoderma lucidum), as represented by 
their similar potential in stimulating neutrophil phagocytosis. The ethanol extract of all the 
polypores were then evaluated for their respective phenolics content, with R. badius possessing a 
similar amount of phenolics as G. lucidum. The results suggest that the phenolics present in R. 
badius could be responsible for its immuno-stimulatory effects. Unfortunately, the amount of β-
glucan was not determined. Elsewhere, Koch et al. (2002) showed that ethanol extracts of R. 
badius were able to reduce LPS-binding to CD14 transfected cells, resulting in an inhibition to the 
production of TH1 proinflammatory cytokines (TNF-α and IL-1β) but a stimulation in the 
production of TH2 pattern cytokine IL-4 and reactive oxygen species (ROS). 
All in all, only the ethanol extracts of R. badius have been reported for their immuno-
modulatory activity, with no solid evidence on the nature (large or small molecule) of the active 
compound, and hence the need to further explore the immuno-modulatory activity of R. badius. 
1.5 Immuno-stimulation as an Approach for Cancer Treatment 
 Immunomodulators are currently considered as important components in modern 
healthcare due to the fact that the immune system serves as the first barrier of defense against 
diseases, and can be categorized into immuno-adjuvants, immuno-stimulants and immuno-
suppressants (El Enshasy & Hatti-Kaul, 2013). Mushroom metabolites are known to exhibit anti-
tumor and immuno-modulating activity which act on immune effecter cells such as dendritic cells, 
hematopoietic stem cells, lymphocytes, macrophages, natural killer cells, and T cells involved in 
both innate and adaptive immunity, and hence elevating the production of cytokines (Moradali et 
al., 2007). These small intracellular protein mediators secreted by immune cells play a role in an 
organism’s immune response and are cross-regulatory, whereby the expression of one cytokine 
pattern can regulate other patterns of cytokine production (Guggenheim et al., 2014). The types of 
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cytokine patterns that are deemed crucial in cancer biology are summarized into four groups as in 
Table 1. Other than measuring cytokine production quantities, assessing immune cells’ activity is 
also a good approach in determining the immuno-stimulatory properties of mushrooms. 
Table 1. Immune response effect with respect to the type of cytokine produced; (modified from 
Guggenheim et al., 2014)  
 
Pattern Cytokines Produced Pattern Effect 
TH1 IFN-γ, IL-12, TNF-α Stimulates immune response to cancer 
TH2 IL-4, IL-5, IL-13 Decrease TH1 
TH3/Tregulatory TGF-β Modulates TH1 
Proinflammatory IL-1, IL-6, IL-8, TNF-α Induce Inflammation 
 
Polysaccharides: 
Currently, many mushrooms are being studied for their bioactivity against cancer and were 
found to exert immuno-stimulatory activity. Recently, a β-1,6-glucan called PCPS was purified 
from a hot water extract of Pleurotus cornucopiae (Paulet) Rolland which exerted potent 
proinflammatory effect in macrophage cells, both in vitro and in vivo, by inducing the TNF-α and 
IL-1β mRNA expression (Minato et al., 2017). Elsewhere, another water-soluble polysaccharide 
called ISP2a was purified from I. obliquus, which expressed its anti-tumor and immuno-
stimulatory activity by inhibiting tumor growth in tumor-bearing mice by over 50% at a dose of 
100 μg/g, stimulating lymphocyte proliferation, macrophage phagocytosis and TNF-α production 
in vivo (Fan et al., 2012). According to Zhang et al. (2013), Ganoderma atrum J.D. Zhao, L.W. 
Hsu & X.Q. Zhang polysaccharide called PSG-1 expressed profound immuno-stimulatory effects 
by stimulating macrophage phagocytosis in CT26 tumor-bearing mice, via the upregulation IL-1β, 
TNF-a and nitric oxide production in a TLR4-dependent signaling pathway. Similarly, another 
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polysaccharide called GSG was isolated from Ganoderma lucidum (Curtis) P. Karst, which 
enhanced the secretion of TNF-α and IL-6 in murine peritoneal macrophages isolated from 
BALB/c mice, which was in line with the significantly increased Concanavalin A splenocytes 
proliferation in mice and the reduced tumor weight observed (Guo et al., 2009). In addition, a 
water-soluble neutral polysaccharide called JP1 was recently purified from the fruiting body of 
Cantharellus cibarius Fr. and the active compound was able to elevate the secretion of IL-6 and 
nitric oxide in RAW 264.7 cells and mouse peritoneal macrophages respectively, indicating the 
purified polysaccharide’s immuno-stimulating activity (Chen et al., 2017). Moreover, Xu et al. 
(2012) described a novel heteropolysaccharide called L2 isolated from the fruiting body of L. 
edodes capable of elevating the production of TNF-α, IL-6 and nitric oxide in RAW 264.7 cells 
through the toll-like receptor 2 (TLR2) signaling pathway. 
Polysaccharide-Protein Complexes: 
Immuno-stimulating polysaccharide-protein complexes have also been characterized from 
various mushrooms. Krestin (PSK) and PSP are well-known mushroom-derived immuno-
modulating and anti-tumor polysaccharide-protein complex; they are classified as biological 
response modifier that triggers T-cell activation and induces the secretion of IFN-γ and IL-2, 
resulting in an increase in the number of leucocytes (Moradali et al., 2007). A recent study 
conducted by Liu et al. (2016) reported a water-soluble polysaccharide-protein complex (PRW1) 
obtained and purified from Polyporus rhinocerus Cooke (now called Lignosus rhinoceros (Cooke) 
Ryvarden) that managed to upregulate the secretion of a variety of cytokines and the release of 
nitric oxide in RAW 264.7 cells with minimum cell cytotoxicity. In addition to that, a fucose-
containing polysaccharide-protein fraction from G. lucidum was shown to enhanced the expression 
of IL-1, IL-2 and IFN-γ, which was in line with increase mouse spleen cell proliferation (Wang et 
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al., 2002). Elsewhere, another polysaccharide-protein complex called GLIS was isolated from G. 
lucidum, which demonstrated its immuno-stimulatory activity by inducing mouse spleen 
lymphocytes proliferation, resulting in the activation of B-cells, which coincided with the slight 
increase in IL-2 (Zhang et al., 2002). Mushroom immuno-stimulating polysaccharide-protein 
complexes were also reported from Tricholoma lobayense R. Heim, noted by the improvement of 
phagocytosis activity of peritoneal exudate cells which was suppressed in tumor-bearing mice, 
along with the increase in TNF-α production (Liu et al., 1996). 
Proteins: 
 Besides polysaccharides and polysaccharide-protein complexes, mushroom proteins alone 
also have the potential to stimulate immune responses. A 9.5 kDa ubiquitin-like protein isolated 
and purified from the fruiting body of Agrocybe cylindracea (now called Cyclocybe aegerita (V. 
Brig.) Vizzini) was reported to express anti-proliferative activity on hepatoma (HepG2) and 
leukemia (M1) cell lines, together with activation of macrophages via nitric oxide induction (Ngai 
et al., 2003). Elsewhere, a homodimer protein purified from the mushroom Trametes versicolor 
(L.) Lloyd was claimed to have significantly augmented the splenocyte and human peripheral 
blood lymphocytes, along with the elevation of nitric oxide and TNF-α levels in LPS-activated 
macrophages. However, despite being able to stimulate the production of immune cells, the nitric 
oxide and TNF-α production remains questionable as LPS itself was able to stimulate cells (Li et 
al., 2011). Mushroom protein FVE isolated from Flammulina velutipes (Curtis) Singer, commonly 
known as Enoki mushroom, was shown to upregulate the expression levels of class I and II major 
histocompatibility complex (MHC) genes, together with CD80 expression on antigen presenting 
cells (APCs) in mice. The isolated FVE also suppressed cell growth in murine hepatoma cancer 
cell line and reduced tumor progression in hepatoma tissues, and the anti-cancer effects was 
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believed to be attributed to the cytokine, IFN-γ (Chang et al., 2010). Another fungal immuno-
modulatory protein (ACA) obtained from the mycelium extract of A. camphorata was 
demonstrated to activate macrophages via the TLR2/MyD88 dependent signaling pathway which 
results in the activation of the NF-κB gene expression, leading to the secretion of proinflammatory 
cytokines such as TNF-α and IL-1β together with a variety of other cytokines and chemokines 
(Sheu et al., 2009). In addition, lectin (VVL) isolated from mushroom, Volvariella volvacea (Bul.) 
Singer potently activated T-lymphocytes compared to well-known immunomodulator 
concanavalin A (Con A) at the same dosage, and the lymphocyte proliferation was activated with 
the rapid expression of CD25, CD69, IL-2, NFAT, and PCNA proteins along with the secretion of 
IFN-γ and IL-2 (Sze et al., 2004).  
Small Molecules: 
Although there have been reports on mushroom small molecules, such as terpenes and 
terpenoids having immunomodulatory activities (El Enshasy & Hatti-Kaul, 2013), to the best of 
my knowledge, there are currently no publications specifying the immuno-stimulatory effect from 
mushroom small molecules. Hence, there should be efforts not only to search for potent immuno-
stimulatory polysaccharides and polysaccharide-protein complexes, but also to screen for novel 
small molecules that could possibly stimulate the immune system. 
In spite of the significant number of publications reporting the immuno-stimulatory effects 
from mushrooms through cytokine and immune cells regulation, when linked with cancer however, 
the secretion of proinflammatory cytokines have the tendency to cause undesired inflammatory 
responses associated with fever symptoms (Guggenheim et al., 2014). Behavioral changes like 
anxiety, depression, fatigue, labile anger, and  psychomotor slowing have also been observed with 
the use of certain cytokines in other disease treatment (Duivis et al., 2013; Lotrich et al., 2010; 
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Miller, 2009; Moreira et al., 2015). With all the side effects taken into account, the use of immuno-
stimulatory compounds for cancer treatment might not seem to be ideal. Nevertheless, the high 
potential of immuno-stimulatory compounds clearly outweighs the minor drawbacks that could 
arise, and therefore is still a promising approach in the treatment of cancer. 
1.6 The Structure and Anti-Cancer Properties of Polysaccharides and Polysaccharide-
Protein Complexes 
 Polysaccharides are macromolecules with large structural diversity as compared to nucleic 
acids and proteins: the monosaccharide unit in polysaccharides can be linked to one another at 
numerous points, forming multiple branches as well as linear chains, whereas there is only a one-
way linkage systems for nucleotides (sugar phosphate backbone) and amino acids (N- and C-
terminus) (Sharon & Lis, 1993).  Moreover, the ability of polysaccharides to form secondary 
structures based on size, sugar residue conformation and inter- and intra-chain hydrogen bonding 
provides the molecule with a much require plasticity for specific cell regulatory mechanisms (Ooi 
& Liu, 2000). Today, immune-modulating polysaccharides and polysaccharide-protein complexes 
in particular, are often the center of attention for scientists due to their effectiveness and low 
cytotoxicity (Liu et al., 2016). Although the exact mechanism whereby polysaccharides or 
polysaccharide-protein complexes act against tumors is still not clear, these large molecules have 
been demonstrated to be biological response modifiers that acts to improve and restore the immune 
system (Ooi & Liu, 2000). The potency of these immuno-modulatory molecules is often associated 
with (i) the molecular weight of the molecule, with the larger one generally being more potent than 
smaller ones, (ii) the degree of branching, with high linearity and little branching generally being 
more biological active, and (iii) the helical conformation, with single and triple helices being the 
most commonly reported polysaccharide structure with immuno-modulatory activities (Meng et 
al., 2016; Ooi & Liu, 2000). 
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1.7 The Promising Potential of Natural Products in Drug Discovery 
Natural products have long been recognized for their traditional role in many drug 
discoveries and were the foundation of many early medicines (Butler, 2005). However, around 
two decades ago, there was a massive decline in interest towards the use of natural products as a 
source for drug discovery by pharmaceutical companies, with many redirecting their attention 
towards synthetic chemical libraries. This was due to  (i) challenges faced in developing and 
maintaining a high quality natural product library, (ii) the labor intensive and time consuming 
downstream process involved in the large-scale production of natural products, (iii) the high risk 
of rediscovering already discovered compound, resulting in replication of data in the database 
which can be problematic to remove, and (iv) challenges faced during compound modification 
(designing of second generation molecules) due to the high degree of stereochemistry natural 
products possess (Lam, 2007).  
Interestingly, despite the large commercially available chemical space of synthetic 
chemical libraries compared to that of the natural product, the use of the former proved to be 
disappointing, hence highlighting the importance of biologically relevant chemical space 
compared to library size. With the current advancement and development of modern technology 
such as improvised functional assays, phenotypic screening processes, and the application of 
genomics, proteomics and metabolomics into natural product screening, together with the 
enormous diversity in natural products, it is expected that pharmaceutical companies will turn their 
focus back to natural products (Harvey et al., 2015). Furthermore, natural products hold numerous 
advantages which are thought to contribute strongly to the drug discovery industry. It is important 
to note that natural products exhibit a high degree of stereochemistry and an extensive array of 
pharmacophores (bioactive molecules with their atoms or chemical groups arranged spatially), 
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which helps improve screening hits even with the more challenging screening targets, such as 
protein-protein interactions. Moreover, the fact that natural products are derived from natural 
origin increases their bioavailability, which is crucial when applied in functional assays such as 
cell-based and animal model testing. Ultimately, the enormous biodiversity of both eukaryotes and 
prokaryotes makes the natural product drug discovery research area relatively untapped, branding 
this field very promising in conjunction with the recent advancement and development of 
technological tools for screening (Harvey et al., 2015). 
Today, natural products are the largest single source of modern anti-cancer agents, with 
almost 50% of the natural anti-cancer drugs discovered between the years of 1940 and 2010 in 
Japan and Western countries (Gurnani et al., 2014). Such an accomplishment further clarifies the 
rationale for using natural products as a hub for the discovery of more novel anti-cancer drugs. 
However, it is also important to note that natural products too come with some disadvantages, 
namely (i) the belief that the process of developing natural products usually lacks proper 
standardization and regulation, (ii) the complexity of the drug discovery process due to 
irreproducibility, inconsistent supply of material, presence of complex mixtures and cost, and (iii) 
the ideology that natural products lack pharmacological efficacy (Carmona & Pereira, 2013). 
1.8 Research Objectives 
 At the outset of this research, Dr. Lee’s lab has shown that the water extract from BC 
mushroom Royoporus badius has strong immuno-stimulatory activity. The research objectives of 
this MSc thesis are: (i) to purify the immuno-stimulatory compound(s) from the water extracts of 
R. badius, and (ii) to biologically and chemically characterize the purified immuno-stimulatory 
compound(s) of R. badius.  
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Chapter 2 
Purification of an Immuno-Stimulatory Compound from the Water 
Extract of Royoporus badius (Pers.) A.B. De 
 Three collections of fresh mushroom specimens of R. badius were made by Dr. Keith Egger 
in the summers of 2016, 2017 and 2018 on rotting wood located in Miworth, BC, Canada and were 
assigned as #86, #150 and #152 respectively. Mushroom #86 was used as the starting material in 
the year of 2017 while mushroom #150 was used in the year of 2018 (after mushroom #86 was 
depleted). Mushroom #152 was also used in 2018.  According to the literature, there have been no 
known immuno-stimulatory compounds identified from R. badius. Thus far, only two studies have 
been performed on the ethanol extracts of R. badius, with one exhibiting mild cytotoxic activity 
against colorectal cancer cell lines (Doskocil et al., 2016), while the other was shown to inhibit 
the production of proinflammatory cytokines but elicited TH2 response (Koch et al., 2002). Despite 
showing the presence of bioactivity in the ethanol extract of R. badius, no efforts were done to 
further purify the bioactive compound.  
Several purification techniques were required to separate the active compound from the 
other inactive compounds. The purification processes were optimized in an attempt to obtain a 
sufficiently pure active compound. The main focus of this chapter will be the description of 
protocols established in purifying the immuno-stimulatory compound from the water extract of R. 
badius. 
Methodology 
2.1 Identification, Chemical Extraction and Immuno-Stimulatory Activity of R. badius. 
2.1.1 Genetic Identification of Mushroom #86 and Mushroom #150 as R. badius 
Fruiting bodies collected were dried in a conventional oven at 55°C for a week until the 
specimens were completely dried. A small voucher specimen was kept in the UNBC herbarium 
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for future reference, another small portion of the dried fruiting body was then dissected for 
genomic DNA (gDNA) identification purposes while the remaining dried mushroom samples were 
pulverized into powder using a food blender. The powder of the mushroom samples was then 
stored in a Ziploc® bag at room temperature for chemical extraction purposes.  
The gDNA of both mushrooms was extracted, amplified, and purified by Dr. Lee and his 
undergraduate students. The ITS 2 region was used for DNA sequencing analysis, with ITS3 and 
NLB4 being the primers used for DNA amplification. Polymerase Chain Reaction (PCR) 
conditions are as shown in Table 2. The refined PCR products were then sent for DNA sequencing 
and the DNA sequences were analyzed followed by comparison using the Basic Local Alignment 
Search Tool (BLAST). A nucleotide BLAST of the mushroom DNA sequences was used to infer 
the identity of the mushroom analyzed. 
Table 2. PCR conditions for DNA amplification. 
 
Temperature Time Cycle 
95°C 5 minutes 1x 
95°C 30 seconds 29x 
52°C 30 seconds 29x 
72°C 30 seconds 29x 
72°C 10 minutes 1x 
4°C Until Collected 1x 
 
2.1.2 Chemical Extraction of R. badius using the DIONEX ASE 50 Speed Extractor 
The chemical extraction protocol has been established in the Dr. Chow Lee’s lab, namely 
the pulverized dried mushroom powder was subjected to sequential chemical extraction using 4 
different solvents. Samples were subjected to extraction with 80% ethanol followed by 50% 
methanol which were expected to isolate any low molecular weight compounds. After that, the 
remains were extracted using water and 5% sodium hydroxide, whereby the water extract was 
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expected to contain water-soluble polysaccharides, while the alkaline extract was expected to 
contain water-insoluble polysaccharides. All solvent extractions were performed using the Dionex 
ASE 350 Speed Extractor (Thermo Fisher) at 65°C and at a pressure of 1500 psi except for the 
sodium hydroxide extract, which was done manually at 65°C as it will corrode the walls of the 
machine. The outline of the extraction process using the Speed Extractor was as follow: 
Dionex ASE 350 Extraction Process Duration 
Static extraction with rinse (80% ethanol) 4 cycles, 15 minutes per cycle 
Static extraction with rinse (50% methanol) 4 cycles, 15 minutes per cycle 
Static extraction with rinse (water)  4 cycles, 15 minutes per cycle 
Final rinse (water)    1 cycle for 90 seconds 
  
Manual Extraction    Duration 
5% sodium hydroxide extraction  6 hours with constant stirring 
 
Mushroom extracts were labeled as E1, E2, E3 and E4 for ethanol, methanol, water, and 
sodium hydroxide extracts respectively. All extracts were concentrated using the roto-evaporator 
and pH neutralized prior to lyophilization using FREEZONE freeze dryer (Labconco). Freeze-
dried samples were then stored at 4°C for subsequent experiments. For long term storage, dried 
samples were stored at -80°C. Figure 1 outlines the chemical extraction and the downstream steps 
taken. 
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 Figure 1. Sequential chemical extraction R. badius (collections #86 and #150) 
2.1.3 Assessing the extracts of R. badius for Immuno-Stimulatory Activity using Murine 
Macrophage (RAW 264.7) Cells 
In order to assess the immuno-stimulatory activity of the extracts from mushrooms #86 and 
#150, a stock of 20 mg/mL from each extract was prepared by resuspending 20 mg of crude extract 
powder in 1 mL of MilliQ water followed by filter sterilization using a 0.22 μm filter (Sarstedt). 
The filter sterilized extracts were then diluted to 2 mg/mL extract using BioWhitaker® Dulbecco’s 
Modified Eagle’s Medium (DMEM) without Fetal Bovine Serum (FBS). 
Murine macrophage (RAW 264.7) cell line was obtained from American Type Culture 
Collection (ATCC) and cultured using BioWhitaker® Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 10% Fetal Bovine Serum (FBS) until 70-80% confluent prior to trypsinizing 
adhering cells with Life Technology TrypLETM Express (Thermo Fisher) for 5-10 min. 
Trypsinized cells were then diluted using BioWhitaker® Dulbecco’s Modified Eagle’s Medium 
(DMEM) without FBS prior to counting the cell density. A total of 200 μL containing 100,000 
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cells in DMEM without FBS were seeded in 96-well plate and incubated at 37°C and 5% carbon 
dioxide (CO2) overnight. 
After the overnight incubation, the medium was removed from the wells and the cells were 
washed with 200 μL of BioWhitaker® Dulbecco’s Phosphate Buffer Saline (PBS). The buffer 
solution was removed and 100 μL of DMEM without FBS was pipetted into each well. The cells 
were treated with 100 μL of the crude extracts prepared, with a final well concentration of 1 mg/mL. 
Controls used in the assay were lipopolysaccharide (LPS) resuspended in DMEM without FBS 
with a final concentration of 500 ng/mL, along with water and DMEM without FBS, all with a 
treatment volume of 100 μL. The RAW 264.7 cells were left to incubate at 37°C and 5% CO2 for 
6 hours prior to collecting the supernatant. Cell morphology was observed prior to collecting the 
supernatant to ensure that no cell-killing has occurred. A total of 100 μL of the cell supernatant 
was collected and transferred to a new 96-well plate. The supernatant was then stored at -80°C. 
ELISA was performed using the BD OptEIATM Mouse TNF (Mono/Mono) ELISA Set A 
and Reagent Set B (BD Bioscience). The assay was conducted in accordance to the manufacturer’s 
protocol and using a 96-well MicrotiterTM polystyrene plates (Thermo Fisher). In short, the 
microwells were first coated with 100 μL of Capture Antibody diluted in Coating Buffer (1:250 
dilution) and incubated at 4°C overnight. During the day in which the assay was performed, each 
well was then washed 3 times with 300 μL of 1x wash buffer and blotted on paper towel till dry. 
The plates were then block with 200 μL of assay diluent, sealed and incubated at room temperature 
for 1 hour. Following that, the plates were again washed 3 times with 300 μL of 1x Wash Buffer 
and blotted on paper towel till dry. The empty wells were then loaded with 100 μL of the 
Recombinant Mouse TNF-α standards resuspended in Assay Diluent (0, 15.6, 31.3, 62.5, 125, 250, 
500, 1000 pg/mL) and the supernatant (diluted 10x or 20x with assay diluent) collected from the 
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RAW 264.7 cells treated with mushroom samples. The plate was then sealed and left to incubate 
at room temperature. After 2 hours, the plates were washed with 5 times with 300 μL of 1x Wash 
Buffer and blotted on paper towel till dry, prior to adding 100 μL of working detector, a mixture 
of Detection Antibody and Streptavidin-Horse Radish Peroxidase reagent diluted in Assay Diluent 
(1:250 dilution). The plates were then sealed and left to incubate for another hour at room 
temperature. After one hour, the plates were then washed 7 times with 300 μL of 1x Wash Buffer 
and blotted on paper towel till dry, followed by the addition of 100 μL of Substrate Solution, an 
equal mixture of Substrate Reagent A and Substrate Reagent B. The plates were then incubated in 
the dark without the sealer for 30 min prior to stopping the reaction with 50 μL of Stop Solution 
into each well. Upon completion of the assay, the microplate was subjected to absorbance reading 
at 450 nm and 570 nm using SYNERGY 2 (Biotek®) and the wavelength correction was 
performed by subtracting the absorbance at 570 nm from the absorbance obtained from 450 nm. 
2.2 Purification of E3 from R. badius using Low Resolution Size-Exclusion 
Chromatography 
2.2.1 Size-Exclusion Chromatography with a Mini-Drip Column using SephadexTM LH-20
 Matrix 
The initial choice of matrix to perform the size-exclusion chromatography was SephadexTM 
LH-20 (GE Healthcare). A total of 6.5 g of dry SephadexTM LH-20 powder swelled in 50 mL of 
degassed MilliQ water for 2 days to yield approximately 20 mL bed volume (BV) resin. On the 
second day, excess water was discarded to make a slurry with a resin to medium ratio of 3:1. To 
construct a 25 mL size column, a 25 mL serological pipette (Sarstedt) was used as the column. 
The top tip of the 25 mL serological pipette was removed using a pair of scissors and the bottom 
tip of the 25 mL serological pipette was stuffed with some cotton wool, acting as a filter to prevent 
the resin from leaking out. The swollen resin was then stirred gently using a spatula to ensure a 
homogenous mixing with its media and then transferred to the self-constructed column. Upon 
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loading of the resin into the column, using a Pasteur pipette, the column was packed and 
equilibrated with 3 BV of degassed MilliQ water. Once the column was successfully packed, a 
stopper was inserted to the bottom tip of the column to stop the flow of the mobile phase. 
A total of 20 mg of E3 from mushroom #86 was measured and resuspended in 1 mL of 
MilliQ water to make up a 20 mg/mL extract solution. The sample was then filter sterilized using 
a 0.22 μm filter (Sarstedt) to remove any insoluble particulates from the sample. The loading 
volume was set at 2% of the total bed volume, hence only 500 μL of the prepared sample was 
loaded manually using a Pasteur pipette into the column with the bottom tip closed with a stopper. 
Once the sample was loaded onto the column, the stopper was removed, MilliQ water was run 
continuously using a Pasteur pipette into the column, and a total of 26 fractions each consisting of 
1 mL volume were collected. The collected fractions were then stored in 4°C until ready to be 
assessed for their immuno-stimulatory activity. 
2.2.2 Size-Exclusion Chromatography with a C26/100 Column using SephadexTM LH-20 
Matrix 
To increase the yield and resolution of the sample separation using SephadexTM LH-20, the 
column size was scaled up to approximately 400 mL BV of matrix. To achieve such a volume, 100 
g of dry SephadexTM LH-20 powder swelled in 1000 mL of degassed MilliQ water for 2 days to 
ensure complete swelling of the resin. After 48 hours, excess water was discarded to make a slurry 
with a resin to medium ratio of 3:1. The swollen resin was then stirred gently using a spatula to 
ensure a homogenous mixing with its media and then transferred to a C26/100 column (GE 
Healthcare). The matrix was then equilibrated and packed with 2-3 BV of MilliQ water with the 
aid of a P-50 pump (Pharmacia Biotech). Following that, 200 mg of sample was measured and 
dissolved in 8 mL of MilliQ water and filtered sterilized using a 0.22 μm filter (Sarstedt) to remove 
any insoluble particulates. A total of 2% loading volume (8 mL) was manually loaded into the 
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packed column and eluted with MilliQ water at a flow rate of 1 mL/min which was maintained by 
the P-50 pump (Pharmacia Biotech). 
A total of 50 fractions, each consisting of 10 mL eluted volume was collected using a 
RediFrac fraction collector (Pharmacia Biotech). The collected fractions were then stored in 4°C 
until ready to be assessed for their immuno-stimulatory activity. 
2.2.3 Assessing the Post LH-20 Fractions for Bioactivity 
The collected post LH-20 fractions were used to treat RAW 264.7 cells and the 
supernatants collected were used in ELISA to quantify the amount of TNF-α produced by the cells. 
The cell treatment and ELISA protocols are as described previously in section 2.1.3, with 
modifications to the volume of the sample treated on cells. In general, 100 μL of the samples 
collected from the fraction collector were used to treat the RAW 264.7 cells. However, should the 
sample result in cell killing, the assay was repeated by lowering the volume used for cell treatment. 
This is because the concentration of each fraction collected is unknown. Fractions that exert 
significant immuno-stimulatory activity were pooled and lyophilized and named 
BRLI_86_E3_LH20. 
2.3 Purification of E3 from R. badius using Anion-Exchange Chromatography 
2.3.1 Determining a Suitable Buffer System for the Anion-Exchange Chromatography with 
a Poly-Prep® Drip Column using DEAE SephadexTM A-50 Matrix 
The choice of matrix to perform the anion-exchange chromatography was the weak anion 
exchanger, DEAE SephadexTM A-50 (Sigma Aldrich), with an approximate 200 kDa exclusion 
limit. To determine a suitable buffer system, a range of amine-based buffers were selected as in 
Table 3. All buffers were classified into two categories, namely the running buffer (20 mM buffer) 
and the elution buffer (1 M NaCl in 20 mM buffer), with the pH all being adjusted to its pKa ± 
0.05. 
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Table 3. List of buffers selected for anion-exchange chromatography. 
Buffer Substance pH Interval (pKa at 25°C) pKa at 25°C 
Piperazine (PPZ) 4.8-5.8 5.33 
Bis Tris 6.0-7.0 6.48 
Water N/A 7.00 
Triethanolamine (TETHN) 7.3-8.3 7.76 
Propane-1,3-diamino (PDA) 8.4-9.4 8.88 
Ethanolamine (ETHN) 9.0-10.0 9.50 
 
To determine a suitable buffer system, 150 mg of dry DEAE SephadexTM A-50 powder 
was measured in a 15 mL Falcon tube (Sarstedt) and 13 mL of the 20 mM running buffer was 
added to it. The mixture was then gently swirled to ensure uniform mixing and left to swell for 2 
days. After 48 hours, excess buffer was removed from each Falcon tube, leaving a matrix to buffer 
ratio of 3:1. The resulting solution was then gently swirled to form a slurry and was then transferred 
using a serological pipette into the Poly-Prep® column with a stopper at the bottom of the column. 
In order to pack and equilibrate the column, the stopper was unplugged and 3-4 BV of 20 
mM running buffer was pipetted manually to the column using a Pasteur pipette. The pH of the 
eluted buffer should be in the range of 6.50 ± 0.1 before proceeding to sample application. Upon 
successful packing of the column, the stopper was plugged in to stop the flow of the buffer. A total 
of 2.5 mg (250 μL of 25 mg/mL) of BRLI_86_E3_LH20 was loaded to the column. Once the 
samples have been loaded, the stopper was removed and the column was flushed with 2-3 BV of 
running buffer and the eluted solution was collected and named “Flow Through”. Once the Flow 
Through has been collected, the column was then flushed with 2-3 BV of elution buffer, and the 
eluted solution collected was named “Elution”. The collected flow through and elution from each 
respective buffer were then dialyzed using 3500 MWCO SnakeSkinTM Dialysis Tubing (Thermo 
Fisher) to remove the buffer and salt, prior to slant freezing and lyophilization. 
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Due to the immeasurable mass of the product yield from both the flow through and elution, 
the samples were simply reconstituted in 1 mL of MilliQ water, filtered sterilized and treated on 
cells. The cell treatment and ELISA protocols are as described previously in section 2.1.3, with 
modifications to the volume of the sample treated on cells. In general, 100 μL of the samples were 
used to treat the RAW 264.7 cells. However, for any sample that resulted in cell killing, the assay 
was repeated by lowering the volume used for cell treatment. This was because the concentration 
of each fraction collected was unknown. Generally, a buffer system was considered to be suitable 
for purifying the active compound if the flow through did not exhibit significant immuno-
stimulatory activity while the elution did. 
2.3.2 Optimization of the Anion-Exchange Chromatography with an Intermediate-Sized 
XK26/40 Column using DEAE SephadexTM A-50 Matrix 
2.3.2.1 Loading of Post LH20 Samples from Mushroom #86 
With the successful establishment of a suitable buffer system (Bis Tris, pH 6.5) to perform 
the anion-exchange chromatography, the purification step was extended to an intermediate scale 
for optimization purposes. To achieve an approximate 75 mL BV matrix, 1.5 mg of dry DEAE 
SephadexTM A-50 powder was measured and swelled in 150 mL of 20 mM BisTris running buffer 
for 2 days. Once the swelling process was completed, excess buffer was discarded to achieve a 
matrix to medium ratio of 3:1. A slurry was formed by gently mixing the swollen matrix with a 
spatula and transferred to the intermediate-sized XK26/40 column (GE Healthcare). The column 
was packed and equilibrated with 3-4 BV of running buffer at 1.5 mL/min which was maintained 
by the P-50 pump (Pharmacia Biotech). The pH of the eluted buffer should be in the range of 6.50 
± 0.1 before proceeding to sample application. 
Sample (BRLI_86_E3_LH20) with different amounts (20 mg and 30 mg) were used to 
investigate the binding capacity of DEAE SephadexTM A-50 matrix. As previously described in 
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section 2.3.1, the column was then flushed with 2-3 BV of running buffer, but with a flow rate of 
1.0 mL/min, and the flow through was collected. Following was the eluting of the column with 2-
3 BV of elution buffer, also with a flow rate of 1.0 mL/min, and the elution was collected. Both 
the flow through and elution collected were then subjected to rota-evaporation to reduce the 
volume prior to dialyzing using 3500 MWCO SnakeSkinTM Dialysis Tubing (Thermo Fisher) to 
remove the buffer and salt. The dialyzed products were then slant frozen and lyophilized. The 
active product from this purification step was named BRLI_86_E3_LH20_DEAE. 
2.3.2.2 Loading of Crude E3 Samples from Mushroom #150 
With the depletion of mushroom #86 and also the inefficiency of the SephadexTM LH-20 
as a first step for purification, it was decided that using DEAE SephadexTM A-50 (GE Healthcare) 
for anion-exchange chromatography will act as the first purification step for mushroom #150. The 
protocol was as previously described in section 2.3.2.1. In order to investigate the binding capacity 
of the matrix, the sample amount loaded was a trial of 40 mg, 60 mg and 100 mg. 
2.3.2.3 Assessing the Binding Capacity of the DEAE SephadexTM A-50 Matrix and the 
Specific Activity of BRLI_#86_E3_LH20_DEAE 
A total of 2 mg of the dried flow through and elution from both mushroom #86 and #150 
were weighed using an analytical microbalance and reconstituted in 1 mL of MilliQ water and 150 
mM NaCl respectively, followed by filter sterilization using a 0.22 μm filter (Sarstedt). A dose-
dependent assay with concentrations of 0, 0.01, 0.025, 0.05, 0.1, 0.25, 0.5 and 1 mg/mL was 
performed to assess the binding capacity of the matrix used. Crude E3 of both mushroom #86 and 
#150 with similar concentrations were also compared. The cell treatment and ELISA protocols are 
as described previously in section 2.1.3, with modifications to the volume of DMEM without FBS 
in each well due to the different concentrations applied. Generally, if the flow through did not 
exhibit significant immuno-stimulatory activity; while the elution did, it can be concluded that the 
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column was not oversaturated with the amount of sample loaded. This is because excess samples 
loaded would have been eluted off the column into the flow through, causing it to be immuno-
stimulatory, 
For the specific activity assay, should the amount of TNF-α produced by the RAW 264.7 
treated with BRLI_#86_E3_LH20_DEAE be equal or higher than that of BRLI_#86_E3_LH20, 
then it was deemed that the purification process had taken place. 
2.3.3 Anion-Exchange Chromatography with a Large-Sized XK50/100 Column using 
DEAE SephadexTM A-50 Matrix 
Upon successful optimization of the binding capacity of the matrix, the purification step 
was scaled up to a large XK50/100 column, with an approximate BV of 750 mL. To achieve the 
BV, 13 g of dry DEAE SephadexTM A-50 powder was measured and mixed with 1 L of 20 mM 
Bis Tris running buffer. The resin was allowed to swell in the buffer for 2 days prior to column 
packing. Once the resin has completely swollen, the resin was gently mixed with a spatula to form 
a slurry and loaded into the XK50/100 column. The column was packed by pumping 3-4 BV of 
20 mM Bis Tris running buffer at a flow rate of 1.5 mL/min. The pH of the eluted buffer should 
be in the range of 6.50 ± 0.1 before proceeding to sample application. 
A total of 860 g of crude sample E3 of mushroom #150 was loaded manually to the column 
and flushed with 2-3 BV of running buffer with a flow rate of 1.0 mL/min. The flow through was 
then discarded. The elution process was then resumed by eluting of the column with 2-3 BV of 
elution buffer (1.0 M NaCl in 20 mM Bis Tris), also with a flow rate of 1.0 mL/min, and the elution 
was collected. The elution collected was then subjected to rota-evaporation to reduce the volume 
prior to dialyzing using 3500 MWCO SnakeSkinTM Dialysis Tubing (Thermo Fisher) to remove 
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the buffer and salt. The dialyzed products were then slant frozen and lyophilized. The active 
product was named BRLI_#150_E3_DEAE. 
2.4 Purification of the Post DEAE Active Fractions from E3 of R. badius using High 
Resolution Size-Exclusion Chromatography 
2.4.1 Hi-Prep Sephacryl S500 Equipped with ÄKTA Pure Fast Protein Liquid 
Chromatography (FPLC) System 
The pre-packed Hi-Prep Sephacryl S500 (GE Healthcare) was used as the final step to 
purify BRLI_#86_E3_LH20_DEAE and BRLI_#150_E3_DEAE. The column was equilibrated 
with 2-3 column volumes (CV) of 150 mM NaCl solution at a flow rate of 1.3 mL/min prior to 
loading the sample. Sample amount ranging from 25 to 115 mg reconstituted in 2 mL of 150 mM 
NaCl were filter sterilized and loaded into the column. The sample was eluted for 1.5 CV at a flow 
rate of 1.3 mL/min and a total of 50 fractions, each consisting of 10 mL was collected using the 
F9-R fraction collector (GE Healthcare). The column was then washed with 1.5 CV of 150 mM 
NaCl before the next sample application. From time to time, the column was subjected to regular 
cleaning with 0.5 CV of 0.2 M NaOH solution followed immediately by 2 CV of MilliQ water and 
equilibration with 3 CV of 150 mM NaCl prior to the next sample application, all with a flow rate 
of 1.3 mL/min. 
2.4.2 Assessing the Fractions Collected for Bioactivity 
2.4.2.1 Post LH20-DEAE-Sephacryl Fractions of Mushroom #86 
All the fractions collected were assessed for immuno-stimulatory activity on RAW 264.7 
cells. The supernatants collected after treatment on cells were used in ELISA to quantify the 
amount of TNF-α produced by the cells. The cell treatment and ELISA protocols are as previously 
described in section 2.1.3, with modifications to the volume of the sample treated on cells. In 
general, 100 μL of the samples collected from the fraction collector were used to treat the RAW 
264.7 cells. However, should the sample result in cell killing, the assay was repeated by lowering 
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the volume used for cell treatment. This was because the concentration of each fraction collected 
was unknown. However, the samples were believed to be contaminated as there was significant 
detectable immuno-stimulatory activity present in all samples, especially the initial few fractions, 
and hence the sample was discarded. Details of the issue are discussed in section 2.11. 
2.4.2.2 Post DEAE-Sephacryl Fractions of Mushroom #150 
Fractions were selected for their immuno-stimulatory activity. The selection was based on 
the chromatogram produced by the ÄKTA Pure FPLC system, where every subsequent fraction 
within the peak region were assessed, while only alternative fractions at the beginning or the end 
were tested. The cell treatment and ELISA protocols are as previously described in section 2.1.3, 
with modifications to the volume of the sample treated on cells. In general, 100 μL of the samples 
collected from the fraction collector were used to treat the RAW 264.7 cells. However, should the 
sample result in cell killing, the assay was repeated by lowering the volume used for cell treatment. 
This was because the concentration of each fraction collected was unknown. Fractions exerting 
strong immuno-stimulatory activity as compared to negative controls were pooled, dialyzed using 
3500 MWCO SnakeSkinTM Dialysis Tubing (Thermo Fisher) to remove the salt, slant frozen, and 
freeze dried. This purified sample was named BRLI_#150_E3_DEAE_Sephacryl. 
2.4.3 Assessing the Specific Bioactivity of BRLI_#150_E3_DEAE_Sephacryl and 
BRLI_#150_E3 
A total of 1 mg of the dried BRLI_#150_E3_DEAE_Sephacryl was weighed using a 
Cubis® Micro Balance (Sartorius) and reconstituted in 1 mL of MilliQ water and subjected to 
filter sterilization using a 0.22 μm filter (Sarstedt). A dose-dependent assay with concentrations of 
0, 0.01, 0.025, 0.05, 0.1, 0.25, and 0.5 mg/mL was used to treat RAW 264.7 cells. Both 
BRLI_#150_E3_DEAE_Sephacryl and BRLI_#150_E3 were added to cells with a similar 
concentration. The cell treatment and ELISA protocols are as described previously in section 2.1.3, 
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with modifications to the volume of DMEM without FBS in each well due to the different 
concentrations applied. Should the amount of TNF-α produced by the RAW 264.7 treated with 
BRLI_#150_E3_DEAE_Sephacryl be equal or higher than that of BRLI_#150_E3, then it is a 
confirmation that the purification process had taken place. 
2.5 Large Scale Production of Post DEAE-Sephacryl Active Fractions from E3 of 
Mushroom #152 
2.5.1 Bulk Extraction of Mushroom #152 by Manual Extraction 
The third batch of R. badius (DNA confirmation pending) was collected in the summer of 
2018 and was used to produce the material needed for further characterization studies. The amount 
of mushroom obtained from the third batch was approximately triple the amount of what was 
collected in both the summers of 2016 and 2017, and hence the use of the Speed Extractor was 
omitted, but rather a manual extraction was performed. A total of 350 g of pulverized dried powder 
of Mushroom #152 were subjected to sequential manual extraction, starting with 80% ethanol at 
65°C for 3 hours. The ethanol extract (E1) was then filtered and the residue was subjected to 
manual extraction using 50% methanol at 65°C for 3 hours. The methanol extract (E2) was then 
filtered and the residue was subjected to manual extraction using water at 65°C for 6 hours. The 
hot water extract (E3) was then filtered and the residue was discarded. The alkaline extract (E4) 
was not performed. All three extracts were then subjected to rota-evaporation, slant freezing at -
80°C followed by lyophilization. The dried powder of all three extracts, were assessed for their 
immuno-stimulatory activity to ensure reproducibility as of the previous batches (mushroom #86 
and #150). 
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2.5.2 Large Scale Purification of E3 from Mushroom #152 using Anion-Exchange 
Chromatography with a Large-Sized XK50/100 Column using DEAE SephadexTM A-
50 Matrix 
The purification protocol was as described in section 2.3.3, but with an increase in loading 
amount from 860 mg of crude E3 powder to 1 g of crude E3 powder. A total of 6 column runs 
were performed, each with a loading amount of 1 g of crude E3 powder from Mushroom #152. 
2.5.3 Large Scale Purification of Post DEAE Active Fractions from Mushroom #152 using 
Hi-Prep Sephacryl S500 Equipped with ÄKTA Pure Fast Protein Liquid 
Chromatography (FPLC) System 
The purification protocol was as described in section 2.4.1. A total of 12 column runs were 
performed, each with a loading amount of approximately 120 mg of Post DEAE active fraction 
powder from E3 of Mushroom #152. The product was named BRLI_#152_E3_DEAE_Sephacryl. 
2.6 Statistical Analysis 
Statistical analysis using One Way ANOVA (Tukey Test) or Student t-Test was performed 
in Graph Prism Version 6.0, whereby the data shown are expressed in mean ± standard deviation 
(SD). 
Results and Discussion 
2.7 Genetic Identity of Mushroom #86 and Mushroom #150 
Both mushroom collections #86 and #150 were made by Dr. Keith Egger at Miworth, BC, 
Canada during the summer of 2016 and 2017 respectively. Based on the method described in 
section 2.1, the mushrooms were genetically identified as Royoporus badius (Table 4). The 
consensus sequence has 98-100% identity to voucher specimens identified as Royoporus badius 
(Pers.) A.B. De or one of its synonyms (e.g. Polyporus badius (Pers.) Schwein.) Recently a new 
name has been proposed, Picipes badius (Pers.) Zmitr. & Kovalenko (Zmitrovich & Kovalenko, 
2016), but it has not yet been widely accepted so I retained the commonly used name Royoporus 
badius. Figures 2 and 3 show photos of the mushrooms collected. 
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Table 4. Summary of mushroom #86 and #150 collected in BC, Canada. 
Mushroom 
Number 
Mushroom 
Identity 
Date 
Collected 
Location in 
BC 
Best GenBank Match 
(%Similarity/%Coverage) 
#86 Royoporus badius August 2016 Miworth KM411465.1 (98%/87%) 
#150 Royoporus badius June 2017 Miworth KM411465.1 (98%/87%) 
 
 
Consensus sequence (CL86 and CL150): 
GAAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACG
CACCTTGCGCTCCTTGGTATTCCGAGGAGCACGCCTGTTTGAGTGTCGTGAAATTCTC
AACCTACAAGGCTTTTGTTTTGTAGGCTTGGACTTGGAGGCGTTGCCGATGTTTTTAT
TTACGTTGGCTCCTCTCAAATGCATTAGCTAGCGTCCTTTGCGGATCAGCTTTTCGGT
GTGATAATTGTCTACGCCGTAGTTGTGAAGCGTTTTTGACCAGCTTCTAATGGTCTTG
TGAAAGAGACAAAAGAAATTTCATTTCAATGACAATCTGACCTCAGATCAGGCGGG
ACTACCCGCTGAACTTAAGCATATCAATAAGCGGAGGAAAAGAAACTAACAAGGAT
TCCCCTAGTAACTGCGAGTGAAGCGGGAAAAGCTCAAATTTAAAATCTGACGGTTTT
GGCCGTCCGAGTTGTAGTCTGGAGAAGTGCTTTCCGCGCTGGACCGTGTATAAGTCT
CTTGGAACAGAGC 
 
 
     
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
     Sequencing match: Royoporus badius (Pers.) A.B. De 
     Mushroom ID: #86 
 
Figure 2. Fresh samples of mushroom #86 collected in Miworth, BC, Canada. 
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Sequencing match: Royoporus badius (Pers.) A.B. De 
     Mushroom ID: #150 
     
Figure 3. Oven-dried samples of mushroom #150 collected in Miworth, BC, Canada. 
 
 
 
2.8 Immuno-Stimulatory Activity of Crude Extracts from Mushroom #86 and 
Mushroom #150 
All mushroom samples collected were oven-dried, pulverized to powder and subjected to 
chemical extraction using the Dionex ASE 350 Speed Extractor (Thermo Fisher) as described in 
section 2.1.2. Tables 5 and 6 provide the percentage yield obtained post extraction of mushroom 
#86 and mushroom #150 respectively. A total of 97.617 g of dried mushroom #86 powder was 
used for chemical extraction, while 123.657 g of dried mushroom #150 powder was used for the 
extraction process. 
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Table 5. Percentage yield from the sequential extraction of mushroom #86. 
Extract Mass Yield (g) Percentage Yield (%) 
E1 1.523 1.56 
E2 2.997 3.07 
E3 2.000 2.05 
E4 ND* ND* 
* Due to low immuno-stimulatory activity, bulk extraction of E4 was omitted and hence the yield 
was not calculated. 
 
Table 6. Percentage yield from the sequential extraction of mushroom #150. 
Extract Mass Yield (g) Percentage Yield (%) 
E1 2.264 1.83 
E2 3.442 2.78 
E3 3.568 2.89 
E4 ND* ND* 
* Due to low immuno-stimulatory activity, bulk extraction of E4 was omitted and hence the yield 
was not calculated. 
 
 The dried extracts from the two respective mushroom samples were then added to RAW 
264.7 cells and their immuno-stimulatory activity assessed as described in section 2.1.3. LPS was 
used as the positive control, while water and media (DMEM without FBS) was used as the negative 
control. All extracts treated to RAW 264.7 cells were at a final concentration of 1 mg/mL and all 
extracts were reconstituted in water. Figures 4a and 4b show the immuno-stimulatory activity 
profile of mushroom #86 and mushroom #150 respectively. 
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Figure 4. (a) The immuno-stimulatory activity profile of the extracts E1, E2, E3 and E4 (1 mg/mL) 
of mushroom #86 treated on RAW 264.7 cells. LPS (500 ng/mL) was used as the positive control 
while water and DMEM without FBS were used as negative controls; (b) The immuno-stimulatory 
activity profile of the extracts E1, E2, and E3 (1 mg/mL) of mushroom #150 treated on RAW 
264.7 cells. LPS (500 ng/mL) was used as the positive control while water and DMEM without 
FBS were used as negative controls. Data presented are representatives from two separate 
experiments. Error bars indicated the SD from the mean. Statistical analysis was assessed using 
One-Way ANOVA (Tukey Test) with *** (P < 0.05) compared to negative control water. 
 
Based on the data obtained from Tables 5 and 6, it was clear that the yield for the extracts 
were very low, ranging from 1.56% to 3.07%. In my thesis, the water extract (E3) was selected as 
the choice for further study. However, it is clear that the limitation of the study was due to the low 
availability of working material. Despite the low availability of the extract from R. badius, the 
water extract of the mushroom exhibited strong immuno-stimulatory activity as compared to that 
of the other extracts and negative controls. The activity profile (all E1 – E4) of mushroom #86 was 
initially screened for bioactivity by Mr. Jatinder Khatra. Upon depletion of the material from 
mushroom #86, the extracts of mushroom #150 were used, and hence a confirmation of the 
bioactivity was necessary. Both the data from Figures 4a and 4b confirmed the presence of the 
immuno-stimulatory activity in the water extracts, E3 of R. badius collected in Miworth, BC. 
4a 
 
4b 
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2.9 Immuno-Stimulatory Activity of the Post LH20 Fractions of Mushroom #86 
Upon confirming the presence of immuno-stimulatory activity in the water extract E3 of R. 
badius, the first approach was to estimate the relative molecular size of the bioactive compound 
by using a size separation technique. LH20 SephadexTM was selected as the matrix for the size-
exclusion chromatography. To start, a Mini-Drip column containing LH20 SephadexTM was used 
with the procedures are as described in section 2.2.1. With the presence of immuno-stimulatory 
activity peaks obtained from the eluted sample of the Mini-Drip LH20 SephadexTM column (data 
not shown), I further improved the separation resolution by upscaling the separation technique 
using a 400 mL LH20 SephadexTM bed volume packed into a C26/100 column. The procedures 
are as described in section 2.2.2. Figure 5 illustrates the immuno-stimulatory profile of the 
fractions collected from a 400 mL C26/100 LH20 SephadexTM column. 
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Figure 5. The immuno-stimulatory activity profile of the 400 mL C26/100 LH20 SephadexTM 
fractions from E3 of mushroom #86. A total of 50 fractions was collected from the column and 
were used to treat RAW 264.7 cells to assess their bioactivity. Data shown is a representation of 
three separate experiments. 
 
 The LH20 SephadexTM matrix is a relatively crude separation matrix, with an exclusion 
limit of approximately 4-5 kDa. Based on the data from the mini-drip column, three immuno-
stimulatory peaks were observed, starting within an elution volume of 9 mL, fraction 9 to 20 mL, 
fraction 20 (data not shown). Despite the interesting activity profile, no conclusion can be made 
as only a small volume (i.e. 20 mL BV) was used as the matrix volume and the entire purification 
process was based on the flow of gravity. In order to obtain a clearer picture, the separation process 
was scaled up to a 400 mL BV column together with a controlled flow rate. Interestingly, only one 
single activity peak was reproducibly observed, which was eluted at approximately between 
130mL (fraction 13) to 170 mL (fraction 17) as depicted in Figure 5. Between the elution volume 
200 mL and 240 mL, minor activity peaks were detected in some experimental replicates but not 
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others (data not shown), and hence was omitted as it was suggested that the compound, if present 
was very unstable. The data suggests that the active compound is a large molecule due to its early 
elution volume.  
2.10 Immuno-Stimulatory Activity of the Post LH20-DEAE Fractions of Mushroom #86 
 Upon completion of the first step purification using LH20 SephadexTM, the resulting active 
products were subjected to a second step purification with Anion-Exchange Chromatography using 
DEAE SephadexTM A-50. Several buffers as previously mentioned in section 2.3.1 were used for 
the selection of the buffer suitable for the purification of the active compound of interest. All flow 
through and elution samples were dialyzed to remove the buffer and salt, followed by 
lyophilization and reconstituted in water prior to testing on RAW 264.7 cells. Figure 6 shows the 
immuno-stimulatory activity profile of the Post LH20-DEAE fractions from E3 of Mushroom #86 
eluted with different buffers in a Poly-Prep® Drip Column packed with DEAE SephadexTM A-50 
matrix. 
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Figure 6. Determination of a buffer suitable for use in DEAE SephadexTM A-50 to purify the 
immuno-stimulatory compound from water extract, E3 of R. badius. The immuno-stimulatory 
activity profile of the flow through and elution of the Post LH20 active fractions on the Poly-Prep® 
drip DEAE SephadexTM A-50 column. Samples were run with various buffer systems as shown. 
The data is a representation of one single experiment. 
 
 Based on the data obtained from Figure 6, it can be observed that the elution of all the six 
solvent systems showed significant immuno-stimulatory activity as compared to that of the flow 
through and the negative controls (water and media), with buffers Bis Tris, Triethanolamine 
(TETHN) and Ethanolamine (ETHN) showing higher activity. In order to confirm the 
reproducibility of the buffer systems in eluting out the active compound, the three aforementioned 
buffers were used in a separate experiment to purify the Post LH20 of E3 from mushroom #86. 
Figure 7 shows the immuno-stimulatory activity profile of the Post LH20-DEAE fractions from 
E3 of Mushroom #86 eluted with Bis Tris, Triethanolamine and Ethanolamine in a Poly-Prep® 
Drip Column packed with DEAE SephadexTM A-50 matrix. 
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Figure 7. Determination of a buffer suitable for use in DEAE SephadexTM A-50 to purify the 
immuno-stimulatory compound from water extract, E3 of R. badius. The immuno-stimulatory 
activity profile of the flow through and elution of the Post LH20 active fractions on the Poly-Prep® 
drip DEAE SephadexTM A-50 column. Samples were run with three buffer systems as shown. The 
data is a representation of two separate experiments. 
 
 Based on Figure 7, it was concluded that the three buffers, Bis Tris, Triethanolamine 
(TETHN) and Ethanolamine (EHTN) were all suitable for the purification of Post LH20 of E3 
from mushroom #86. The buffer Bis Tris was selected as the buffer of choice as it takes a shorter 
amount of time to equilibrate the column due to its relatively lower pH (pKa) value compared to 
that of Triethanolamine and Ethanolamine. With the establishment of the optimum buffer system, 
I then proceeded with optimizing the binding capacity of the DEAE SephadexTM A-50 matrix as 
described in section 2.3.2.1. Because the active compound had previously undergone a first step 
purification using LH20 SephadexTM, it was believed that the loading capacity would have been 
lower due to a higher content of the actual active compound relative to the impurities per weight. 
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Figures 8a and 8b demonstrates the immuno-stimulatory activity profile of the flow through, 
elution and preload (Post LH20 of E3 from mushroom #86) treated on RAW 264.7 cells in a dose-
dependent manner based on different loading amounts into the DEAE intermediate column. 
 
Figure 8. (a) The immuno-stimulatory activity profile of the flow through, elution and Post LH20 
fractions from Mushroom #86. RAW 264.7 cells were treated in a dose-dependent manner as 
shown. The samples were from 30 mg of Post LH20 loaded onto the 75 mL intermediate DEAE 
column; (b) The immuno-stimulatory activity profile of the flow through, elution and Post LH20 
fractions from Mushroom #86. The samples were from 20 mg of Post LH20 loaded onto the 75 
mL intermediate DEAE column. Data presented is from one experiment. 
 
 The initial trial involved loading 30 mg of Post LH20 fractions of mushroom #86 onto the 
75 mL DEAE column, which resulted in an increase in immuno-stimulatory activity of the flow 
through compared to the negative control, water (0 mg/mL) as depicted in Figure 8a. This 
suggested that the column was over-saturated by the loaded sample and hence a lower amount 
should be loaded in the future. In the second trial, a total of 20 mg of Post LH20 fractions of 
Mushroom #86 was loaded into the 75 mL DEAE column, which resulted in insignificant immuno-
stimulatory in the flow through compared to the negative control, elution and preload as illustrated 
in Figure 8b. This confirms the suitable loading capacity and the amount (20 mg) was used for 
the subsequent purification of the Post LH20 fractions of mushroom #86. Based on Figures 8a 
8a 
 
8b 
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and 8b, the preload exhibited cytotoxicity to the RAW 264.7 cells and doses greater than 0.1 
mg/mL, whereas the eluted fraction did not show any cytotoxicity at concentrations up to 0.25 
mg/mL. Such an observation also suggests the removal of the cytotoxic impurities that may have 
been initially present in the Post LH20 fraction prior to DEAE purification, thus indicating the 
success in the purification step using DEAE SephadexTM A-50. 
2.11 Immuno-Stimulatory Activity of the Post LH20-DEAE-Sephacryl Fractions of 
Mushroom #86 
Upon completion of the second step purification using DEAE SephadexTM A50, the 
resulting active fraction, BRLI_#86_E3_LH20_DEAE was subjected to a third purification step 
using Hi-Prep Sephacryl S500 equipped with ÄKTA Pure FPLC system. Figure 9 shows the 
immuno-stimulatory activity profile of the Post LH20-DEAE-Sephacryl fractions of E3 from 
mushroom #86 treated on RAW 264.7 cells. 
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Figure 9. The immuno-stimulatory activity profile of the fractions of Post LH20-DEAE-Sephacryl 
fractions of E3 from mushroom #86 treated on RAW 264.7 cells. Data presented is from one 
experiment. 
 
 Based on Figure 9, there was a significant TNF-α stimulation in RAW 264.7 cells treated 
with the all fractions collected from Hi-Prep Sephacryl S500 column relative to the negative 
control, 150 mM NaCl solution (data not showed), especially the first few fractions early in the 
elution volume. The activity detected is not likely to be from the active compound purified as the 
highest activity peak was detected in the first fraction, which is illogical due to the fact that the 
flow rate of the purification process was controlled and it will definitely require time for the 
samples to pass through the column. Hence, it was concluded that the samples were likely 
contaminated. Unfortunately, the source of the contamination was unknown. The sample loaded 
into this column was all of the remaining sample and hence no replicate could not be carried out. 
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2.12 Immuno-Stimulatory Activity of the Post DEAE Fractions of Mushroom #150 
With the depletion of material from mushroom #86, I resumed my studies with the water 
extracts, E3 from mushroom #150, whereby its immuno-stimulatory activity has been confirmed 
as demonstrated in Figure 4b. In order to have a more efficient purification process, the use of 
LH20 SephadexTM was excluded, simply because the data obtained from previous LH20 
SephadexTM experiments suggested that the active compound is a mixture of carbohydrate (see 
section 3.14) and protein (data not shown), which are basically large molecules and are very likely 
to exceed the exclusion limit (4-5 kDa) of LH20 SephadexTM. Hence, the crude E3 extracts were 
directly subjected to anion exchange chromatography purification using the DEAE SephadexTM 
A-50. According to the data obtained in section 2.10, Bis Tris was a suitable buffer for the further 
purification of BRLI_#86_E3_LH20 and the optimum loading capacity per 75 mL BV DEAE 
SephadexTM A-50 was 20 mg. However, because the current sample, i.e. E3 from mushroom #150 
had yet to undergo any purification step, it was thought that the loading capacity would be higher 
compared to that of BRLI_#86_E3_LH20. As described in section 2.3.2.2, a total of 40, 60 and 
100 mg of E3 from mushroom #150 were loaded on a 75 mL BV DEAE SephadexTM A50 column 
to check for the loading capacity. Figure 10 shows the immuno-stimulatory activity profile of the 
flow through, elution and preload (E3) of mushroom #150 treated on RAW 264.7 cells in a dose-
dependent manner when 100 mg of E3 of mushroom #150 was loaded into the 75 mL intermediate 
DEAE column. 
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Figure 10. Immuno-stimulatory activity profile of the flow through, elution and preload treated 
on RAW 264.7 cells in a dose-dependent manner when 100 mg of E3 of mushroom #150 was 
loaded into the 75 mL intermediate DEAE column. The data presented is a representation of two 
separate experiments.  
 
 The data obtained from Figure 10 shows that even when 100 mg of E3 of mushroom #150 
was loaded into the 75 mL DEAE SephadexTM column, the column matrix was not oversaturated, 
as depicted by the low immuno-stimulatory activity detected in the flow through. Hence, the large-
scale purification of E3 of mushroom #150 was performed as described in section 2.3.3 to obtain 
the semi-purified BRLI_#150_E3_DEAE. 
2.13 Immuno-Stimulatory Activity of the Post DEAE-Sephacryl Fractions of Mushroom 
#150 
Upon the completion of the first step purification of mushroom #150 using DEAE 
SephadexTM A-50, the product BRLI_#150_E3_DEAE was subjected to a second step purification 
using Hi-Prep Sephacryl S500 equipped with ÄKTA Pure FPLC system. The purification methods 
48 
 
are as described in section 2.4.1. Figure 11 shows a representation of the immuno-stimulatory 
activity profile from the fractions collected from the Sephacryl S500 column. 
 
Figure 11. Immuno-stimulatory activity profile of the Sephacryl S500 column eluted fractions. 
Data presented is a representation of five separate experiments.  
 
The data obtained from Figure 11 is completely different from the data obtained in Figure 
9 (suggested to be contaminated). The immuno-stimulatory activity of 
BRLI_#86_E3_LH20_DEAE_Sephacryl collected was detected in fractions of the early elution 
volume, whereas BRLI_#150_E3_DEAE_Sephacryl showed a peak activity at around an elution 
volume of 250 mL (fraction 28), and the activity was confirmed using 5 independent experiments 
(n=5). Hence, it can be concluded that BRLI_#86_E3_LH20_DEAE_Sephacryl was contaminated 
and was discarded. The purified BRLI_#150_E3_DEAE_Sephacryl was then used for subsequent 
characterization studies as will be discussed in Chapter 3. 
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2.14 Specific Bioactivity of the Purified Immuno-Stimulatory Compound from Mushroom 
#150 
To determine whether the active compound was successfully purified, the specific 
immuno-stimulatory activity of the purified compound was compared to that of the less pure form, 
i.e. crude E3 and Post DEAE of mushroom #150. Figure 12 shows the specific bioactivity of the 
three samples. Based on the data, it can be observed that at 0.4 mg/mL, the bioactivity of the Post 
DEAE-Sephacryl compound was more potent as compared to that of the Post DEAE and the crude 
E3, which indicates a successful purification of the bioactive compound of interest. Unfortunately, 
due to insufficient material from the crude E3 and semi-purified post DEAE fraction, the 
experiment was done only once. 
 
Figure 12. Specific immuno-stimulatory activity profile of crude extract E3, Post DEAE and Post 
DEAE-Sephacryl of mushroom #150. Presented data is a representation of one single experiment. 
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2.15 Reproducibility Check on the Extraction and Purification Product of Mushroom #152 
All three extracts obtained from the manual extraction of mushroom #152 as described in 
section 2.5.1 were lyophilized into powder. Table 7 shows the percentage yield obtained post 
extraction of mushroom #152, while Table 8 outlines the percentage yield after each downstream 
process of mushroom #152. A total of 350 g of dried mushroom #152 was subjected to manual 
extraction, yielding a total of 16.368 g (4.68%), 17.314 g (4.95%), and 8.945 g (2.56%) of crude 
extracts E1, E2 and E3 respectively. From there, a total of 6.00 g of crude E3 was subjected to 
DEAE SephadexTM purification, yielding 1.652 g (27.53%) of BRLI_#152_E3_DEAE. Following 
that, a total of 1.595 g of BRLI_#152_E3_DEAE was subjected to Sephacryl S500 column, 
yielding 206.6 mg (12.95%) of BRLI_#152_E3_DEAE_Sephacryl. 
Table 7. Percentage yield from the sequential extraction of mushroom #152. 
Extract Mass Yield (g) Percentage Yield (%) 
E1 16.368 4.68 
E2 17.314 4.95 
E3 8.945 2.56 
E4 ND* ND* 
* Due to low immuno-stimulatory activity, bulk extraction of E4 was omitted and hence the yield 
was not calculated. 
 
Table 8. Percentage yield from each downstream processing of mushroom #152. 
Downstream Process 
Starting 
Amount (g) 
Percentage 
Yield (%) 
Final Product 
Manual Extraction 350 2.56 BRLI_#152_E3 
DEAE SephadexTM 6.00 27.53 BRLI_#152_E3_DEAE 
Sephacryl S500 1.595 12.95 BRLI_#152_E3_DEAE_Sepahcryl 
 
Based on Table 7, the percentage yield obtained for all the three extracts were less than 
5%, which was similar to what was obtained for mushroom #86 and mushroom #152. Despite the 
low yield, the abundance in the starting material (350 g) compared to approximately 100 g each 
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from the previous two batches, should provide sufficient material for further downstream 
purification and characterization studies. 
The immuno-stimulatory activity of all three crude extracts were assessed to ensure 
reproducibility prior to further downstream purification. Figure 13 shows the immuno-stimulatory 
activity profile of mushroom #152. Based on Figure 13, it was concluded that the activity profile 
of E1, E2 and E3 of mushroom #152 was similar and reproducible compared to that of mushroom 
#86 and mushroom #150, with the water extract E3 being the most potent, followed by the 
methanol extract E2 and the ethanol extract E1.  
 
Figure 13. The immuno-stimulatory activity profile of the extracts E1, E2, and E3 (0.5 mg/mL) 
of mushroom #152 treated on RAW 264.7 cells. LPS (500 ng/mL) was used as the positive control 
while water and DMEM without FBS were used as negative controls. Data presented is a 
representation of two separate experiments. Error bars indicated the SD from the mean. Statistical 
analysis was assessed using One-Way ANOVA (Tukey Test) with *** (P < 0.05) compared to 
negative control water. 
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With the confirmation of the presence of immuno-stimulatory activity in E3 of mushroom 
#152, the lyophilized powder of the extract was then subjected to large scale DEAE SephadexTM 
purification. Figure 14 shows the immuno-stimulatory activity profile of the flow through, elution 
and preload (E3) of mushroom #152 treated on RAW 264.7 cells in a dose-dependent manner 
when 1 g of E3 from mushroom #152 was loaded into the 750 mL large DEAE column. 
 
 
Figure 14. Immuno-stimulatory activity profile of the flow through, elution and preload treated 
on RAW 264.7 cells in a dose-dependent manner when 1 g of E3 from mushroom #152 was loaded 
into the 750 mL large DEAE column. Data presented is a representation of two separate 
experiments.  
 
Based on Figure 14, it is clear that despite increasing the loading capacity from 860 mg to 
1000 mg per 750 mL DEAE SephadexTM column, there was still no significant immuno-
stimulatory activity detected in the flow through, and hence confirming that the column was not 
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oversaturated. On the other hand, the elution exhibited comparable immuno-stimulatory activity 
as to the crude extract E3 up to 0.5 mg/mL, and hence, the elution was concentrated, dialyzed, and 
lyophilized for the second purification step using the Hi-Prep Sephacryl S500 column. Figure 15 
shows a representation of the immuno-stimulatory activity profile from the fractions collected from 
the Sephacryl column. 
 
 
Figure 15. Immuno-stimulatory activity profile of the Sephacryl S500 column eluted fractions. 
Data presented is a representation of two separate experiments.  
 
The immuno-stimulatory activity of BRLI_#152_E3_DEAE_Sephacryl showed a peak 
activity at around an elution volume of 250 mL (fraction 28), which was similar to the activity 
profile observed with BRLI_#150_E3_DEAE_Sephacryl. Hence, this confirms the reproducibility 
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of the immuno-stimulatory activity of E3 from mushroom #152 and will be used for further 
purification and characterization upon the depletion of BRLI_#150_E3_DEAE_Sephacryl in 
Chapter 3 of this thesis. 
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Chapter 3 
Characterization of an Immuno-Stimulatory Compound from the 
Water Extract of Royoporus badius (Pers.) A.B. De 
 Mushroom polysaccharides and polysaccharide-protein complexes have often been 
regarded for their immuno-modulatory potential (Ooi & Liu, 2000). Hence, efforts were made to 
purify and characterize an immuno-stimulatory compound from E3 of R. badius. An understanding 
of the chemical and biological properties of ISPP-Rb will provide insightful knowledge to future 
studies conducted to understand the molecular mechanism of ISPP-Rb if it were to be used for 
pharmacology and drug development studies. This chapter describes the experiments conducted 
to characterize and understand the chemical and biological nature of the purified bioactive 
compound (BRLI_#150_E3_DEAE_Sephacryl, see Chapter 2), which was named as ISPP-Rb 
(Immuno-Stimulatory Polysaccharide-Protein from R. badius).  
Carbohydrate, protein and α/β-glucan quantification were performed to determine the 
chemical constituents of the compound. In addition to that, the size of the large molecule was 
estimated. Enzyme assays were conducted to understand the essential component of the molecule 
responsible for its immuno-stimulatory activity. Types of glycosidic linkages and monosaccharide 
content were determined using gas chromatography-mass spectrometry/flame ionization detector 
(GC-MS/FID) respectively. A colorimetric assay was also performed to determine if the active 
compound contain a triple helix structure. Other than that, the protein portion of the proteoglycan 
was also analyzed for the presence of O-linked glycosidic bonds. A Mouse Cytokine 32-Plex 
Discovery Assay was used to determine the types of cytokines and chemokines induced by the 
purified immuno-stimulatory compound. Based on the type of cytokines and chemokines induced 
by ISPP-Rb, a colorimetric-based phagocytosis assay was attempted in an effort to demonstrate 
the biochemical action of the purified compound. 
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Methodology  
3.1 Carbohydrate Quantification using Phenol-Sulphuric Acid Method 
 For both size-exclusion chromatography (SephadexTM LH-20 and Sephacryl S500) and 
ion-exchange chromatography (DEAE SephadexTM A-50), the fractions collected were assessed 
for the carbohydrate content using 96-well MicrotiterTM polystyrene plates (Thermo Fisher). A 
total of 50 μL sample or glucose standard (0, 25, 50, 75, 100, 250, 500, 750, and 1000 μg/mL) was 
aliquot into their designated wells, followed by the addition of 50 μL of 6% phenol solution. The 
resulting solution was subjected to hydrolysis with the addition of 125 μL of concentrated 
sulphuric acid. The 96-well plate was left to incubate at room temperature for 20 min without the 
lid prior to reading the absorbance at 490 nm using the SYNERGY 2 (BIOTEK®) multiplate 
reader. 
3.2 Protein Quantification using Bicinchoninic Acid Assay (BCA assay) 
The protein content of the fractions collected from both size-exclusion chromatography 
(SephadexTM LH-20 and Sephacryl S500) and ion-exchange chromatography (DEAE SephadexTM 
A-50) was analyzed using PierceTM BCA Protein Assay Kit (Thermo Scientific) in 96-well 
MicrotiterTM polystyrene plates (Thermo Fisher). The assay was performed by first putting 10 μL 
of sample or bovine serum albumin (BSA) standard (0, 25, 125, 250, 500, 750, 1000, 1500 and 
2000 μg/mL) into their designated wells, followed by the addition of 200 μL of working reagent 
(BCA Reagent A:BCA Reagent B working ratio = 50:1). The 96-well plate was vortex at 800 rpm 
for 30 sec using a Micro Plate Shaker (VWR®) and was left to incubate at 37°C for 30 min prior 
to reading the absorbance value at 562 nm using the SYNERGY 2 (BIOTEK®) multiplate reader. 
3.3 Total Carbohydrate and Protein Content Quantification of ISPP-Rb 
In order to quantify the total protein content, a total of 1 mg of both ISPP-Rb powder was 
weighed out using a Cubis® Micro Balance (Sartorius). The sample was then reconstituted in 1 
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mL of MilliQ water to make a sample concentration of 1 mg/mL. The sample was then subjected 
to BCA assay to quantify its total carbohydrate content and total protein content respectively. The 
assay procedures were as previously described in section 3.2. The total carbohydrate content was 
quantified based on the GC-FID analysis for monosaccharide content analysis (described in more 
details in section 3.7). The percentage of carbohydrate and protein content with respect to the 
sample mass was calculated using the formula stated below. 
Percentage Carbohydrate (%) =
Total Carbohydrate Concentration (μg mL⁄ )
Sample Concentration (μg mL⁄ )
 
Percentage Protein (%) =
Total Protein Concentration (μg mL⁄ )
Sample Concentration (μg mL⁄ )
 
 
3.4 Size Estimation of ISPP-Rb using Hi-Prep Sephacryl S500 Equipped with ÄKTA 
Pure Fast Protein Liquid Chromatography (FPLC) System 
Dextran T50, T80, T270, T410, T670, and Dextran Blue T2000 (Sigma Aldrich) were used 
to calibrate the column prior to running both the semi-purified BRLI_#86_E3_LH20_DEAE and 
BRLI_#150_E3_DEAE. The flow rate was set to 1.3 mL/min and the buffer used was degassed 
150 mM NaCl in MilliQ water. The combination of dextran used in plotting the trendline are 
indicated in Table 9. The retention volumes obtained from each run were plotted using a 
logarithmic trendline which allows estimation of the molecular weight of the purified immuno-
stimulatory compound. 
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Table 9. Combination of dextran used to calibrate the Hi-Prep Sephacryl S500. 
Run Combination Set Mass (mg) Dextran Size (kDa) 
Run 1 
5.000 670 
5.000 270 
10.000 80 
Run 2 
5.000 410 
10.000 50 
Run 3 0.625 2000 
 
 
3.5 α/β-Glucan Quantification of ISPP-Rb 
The quantification of the α/β-Glucan content of ISPP-Rb was performed using the 
Mushroom and Yeast Beta-Glucan Assay Kit (Megazyme) with modification to the recommended 
protocol. 
3.5.1 Measurement of Total Glucan (α-Glucan + β-Glucan) Plus D-Glucose in 
Oligosaccharides, Sucrose and Free D-Glucose 
A total of approximately 10.0 mg of ISPP-Rb, Phaeolepiota. aurea (Matt.) Maire ex 
Konrad & Maubl polysaccharide sample (provided by Ms. Vicky Myhre, a former graduate student) 
and yeast control were measured into a Screw Cap Flint Glass Vial, 3.5 mL, 15 mm x 45 mm 
(VWR International). The vial was then gently tapped to ensure that all of the sample falls to the 
bottom of the tube. A total of 200 μL of ice cold 12 M sulphuric acid was pipetted to each vial. 
The vials were then capped and the tubes were vigorously stirred on a vortex mixer before placing 
the vials in an ice-water bath for 2 hours with occasional vortex mixing. After 2 hours, 400 μL of 
MilliQ water was added to each vial, capped, and vigorously stirred on a vortex mixer for 10 sec, 
followed by the addition of 600 μL of MilliQ water. The vial was then capped and vortexed for 
another 10 sec. The vials were then transferred to the Isotemp Dry Heating Block (Fisher Scientific) 
set to 100°C with the caps loosened. After 5 min, the caps were tightened and the vials were left 
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to incubate for 2 hours. After the incubation period, the vials were removed from the heating block 
and cooled the tubes to room temperature before loosening the caps. The contents in the vial were 
then quantitatively transferred using a 100 μL pipette to a 10 mL volumetric flask and the remains 
in the vial were rinsed with 5 mL of 200 mM sodium acetate buffer (pH 5) prior to transferring to 
the 10 mL volumetric flask. Then, 600 μL of 10 M KOH solution was pipetted to the volumetric 
flask and the volume was adjusted with 200 mM sodium acetate buffer (pH 5). The contents were 
well mixed by inversion and the contents all the contents were transferred to a 15 mL Falcon tube 
(Sarstedt) and centrifuged using the Allegra X-12R Centrifuge (Beckman Coulter) centrifuge at 
1,500 g for 10 min. 
A total of 10 μL of the supernatant (in duplicates) of the centrifuged extract (ISPP-Rb, P. 
aurea polysaccharide and yeast control) was transferred to a 1.5 mL Eppendorf tube followed by 
the addition of 10 μL of a mixture of exo-1,3-β-glucanase (20 U/mL) plus β-glucosidase (4 U/mL) 
in 200 mM sodium acetate buffer (pH 5.0). The same procedure was performed with the glucose 
and negative control, with a total of 10 μL of the 1 mg/mL Glucose Standard solution or 200 mM 
sodium acetate buffer (pH 5) mixed with 10 μL of a mixture of exo-1,3-β-glucanase (20 U/mL) 
plus β-glucosidase (4 U/mL) in 200 mM sodium acetate buffer (pH 5.0). The resulting solution 
was then gently vortexed and incubated using the Isotemp Dry Heating Block (Fisher Scientific) 
at 40°C for 60 min. After incubation, 300 μL of GOPOD Reagent was pipetted to each tube and 
further incubated at 40°C for 20 min. Upon completion, 100 μL of the solution was pipetted to a 
96-wells UV plate and the absorbance of all solutions (ISPP-Rb, P. aurea polysaccharide, yeast 
control, negative control and glucose control) was measured at 510 nm against the reagent blank 
using SYNERGY 2 (Biotek®). 
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3.5.2 Measurement of α-Glucan (Phytoglycogen and Starch) Plus D-Glucose in Sucrose and 
Free D-glucose. 
A total of approximately 10.0 mg of ISPP-Rb, P. aurea polysaccharide and yeast control 
were measured into a Screw Cap Flint Glass Vial, 3.5 mL, 15 mm x 45 mm (VWR International). 
The vial was then gently tapped to ensure that all of the sample falls to the bottom of the tube, 
followed by the addition of 200 μL of 2 M potassium hydroxide (KOH) solution. The vials were 
then capped and hand-shaken on an ice-water bath for 20 min and proceeded with the addition of 
800 μL of 1.2 M sodium acetate buffer (pH 3.8) and 20 μL of amyloglucosidase (1,630 U/mL) 
plus invertase (500 U/mL). The vials were then left to incubate at 40°C for 30 min in the Isotemp 
Dry Heating Block (Fisher Scientific) with occassional mixing on a vortex stirrer. Later, the 
contents were then transferred using a 100 μL pipette to a 1.5 mL Eppendorf tube and centrifuged 
at 1,500 g for 10 min using the bench top Centrifuge 5424 (Eppendorf). A total of 10 μL of the 
supernatant (in duplicates) were pipetted a separate 1.5 mL Eppendorf tube, followed with the 
addition of 10 μL of sodium acetate buffer (200 mM, pH 5.0) plus 300 μL of GOPOD reagent and 
incubate at 40°C for 20 min in the Isotemp Dry Heating Block. The same procedure was performed 
with the positive control (glucose) and negative control (sodium acetate buffer), with a total of 10 
μL of the 1 mg/mL Glucose Standard solution or 200 mM sodium acetate buffer (pH 5) mixed 
with 300 μL of GOPOD reagent. Upon completion, 100 μL of the solution was pipetted to 96-well 
UV plate and the absorbance of all solutions (ISPP-Rb, P. aurea polysaccharide, yeast control, 
negative control and glucose control) were measured at 510 nm against the reagent blank using 
SYNERGY 2 (Biotek®). 
3.5.3 Estimation of Total β-Glucan Content in ISPP-Rb 
The calculations were performed based on the manufacturer’s guidelines with slight 
modification. The calculation formulas are as listed below and are as provided by the manufacturer. 
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𝑇𝑜𝑡𝑎𝑙 𝐺𝑙𝑢𝑐𝑎𝑛 (% 𝑤 𝑤⁄ ) 𝑝𝑙𝑢𝑠 𝑂𝑙𝑖𝑔𝑜𝑚𝑒𝑟𝑠 =  ∆𝐸 × 𝐹 𝑊⁄  × 90 
𝛼 𝐺𝑙𝑢𝑐𝑎𝑛 (% 𝑤 𝑤⁄ ) 𝑝𝑙𝑢𝑠 𝑂𝑙𝑖𝑔𝑜𝑚𝑒𝑟𝑠 =  ∆𝐸 ×  𝐹 𝑊⁄  × 9.27 
𝛽 𝐺𝑙𝑢𝑐𝑎𝑛 (% 𝑤 𝑤⁄ ) = 𝑇𝑜𝑡𝑎𝑙 𝐺𝑙𝑢𝑐𝑎𝑛 𝑝𝑙𝑢𝑠 𝑜𝑙𝑖𝑔𝑜𝑚𝑒𝑟𝑠 − 𝛼 𝐺𝑙𝑢𝑐𝑎𝑛 𝑝𝑙𝑢𝑠 𝑂𝑙𝑖𝑔𝑜𝑚𝑒𝑟𝑠 
where: 
ΔE   = reaction absorbance – blank absorbance. 
F   =  
10 𝜇𝑔 𝑜𝑓 𝑡௛𝑒 𝐷−𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
𝐺𝑂𝑃𝑂𝐷 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑓𝑜𝑟 10𝜇𝑔 𝑜𝑓 𝐷−𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
 
W   = weight of sample analyzed. 
90 and 9.27 = Volume correction factor multiplied by a factor to convert from free D-
glucose to anhydroglucose, as occurs in β-glucan. 
 
3.6 Enzyme Assay Analysis on ISPP-Rb using Enzyme Degradation Assays. 
The enzyme assay was performed in two separate stages. The first stage was carried out 
prior to obtaining the carbohydrate linkage data from GC-MS, while the second stage was carried 
out after obtaining the carbohydrate linkage data from GC-MS. 
3.6.1 Enzyme Degradation Assay using Proteinase K and α-Amyloglucosidase  
For the first stage, pooled active fractions of Sephaceyl S500 (ISPP-Rb) from one 
purification run were used to study the effect of certain enzymes on its immuno-stimulatory 
activity. Due to the immeasurable mass of the purified product, the freeze-dried powder was 
simply reconstituted in 3.5 mL of MilliQ water and filter sterilized using a 0.22 μm filter (Sarstedt). 
A total of 7 mg of Krestin (PSK, purchased in a local shop in Hong Kong) was weight out using a 
Cubis® Micro Balance (Sartorius) and resuspended in 3.5 mL of MilliQ water to make a 
concentration of 2 mg/mL, and the resulting solution was then filter-sterilized. Enzymes used in 
this assay were Proteinase K (New England Biolabs) and α-amyloglucosidase from Aspergillus 
niger (Sigma Aldrich). The enzyme Proteinase K (PK) was a 20 mg/mL stock solution, while the 
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enzyme α-amyloglucosidase (AMG) was a 5 mg lyophilized powder, with every 1 mg accounting 
for 30-60 activity units (U). To prepare the enzyme AMG in solution form, all 5 mg were 
reconstituted in 1 mL of MilliQ water, and it was assumed that every 1 mg of the protein will 
contribute to 45 activity units (median value). The sample-enzyme mixture set up is as depicted in 
Table 10-13. All samples were incubated at 37°C for 2 hours, followed by heat deactivation at 
80°C for 20 min, with the exception of ISPP-Rb* and PSK*, which were only subjected to the 2 
hours incubation at 37°C, and not heat deactivation. After heat deactivation, the samples will be 
stored at 4°C prior to addition to RAW 264.7 cells the following day. 
The cell treatment and ELISA protocols are as described previously in section 2.1.3, with 
modifications to the volume of DMEM without FBS in each well due to the different doses applied. 
For this assay, 100 μL of the enzyme-treated mushroom polysaccharide samples were used to treat 
the RAW 264.7 cells.  
Table 10. Preparation of the treatment of ISPP-Rb with Proteinase K (PK) and α-amyloglucosidase 
(AMG). 
Sample/Enzyme 
PK (0.4 mg/mL) PK (2 mg/mL) AMG (1.0 U) AMG (10.0 U) 
Volume (μL) 
Purified Compound 300 300 300 300 
PSK (2 mg/mL) NIL NIL NIL NIL 
PK (20 mg/mL) 5.0 25.0 NIL NIL 
AMG (45 U/mL) NIL NIL 4.50 45.0 
MilliQ Water 45.0 25.0 45.5 5.00 
Total Volume 350.0 
*Only subjected to the 2 hours incubation at 37°C but not heat deactivation. 
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Table 11. Preparation of the treatment of positive control, PSK with Proteinase K (PK) and α-
amyloglucosidase (AMG). 
Sample/Enzyme 
PK (0.4 mg/mL) PK (2 mg/mL) AMG (1.0 U) AMG (10.0 U) 
Volume (μL) 
Purified Compound NIL NIL NIL NIL 
PSK (2 mg/mL) 300 300 300 300 
PK (20 mg/mL) 5.0 25.0 NIL NIL 
AMG (45 U/mL) NIL NIL 4.50 45.0 
MilliQ Water 45.0 25.0 45.5 5.00 
Total Volume 350.0 
*Only subjected to the 2 hours incubation at 37°C but not heat deactivation. 
Table 12. Preparation of negative controls, water treated with Proteinase K (PK) and α-
amyloglucosidase (AMG). 
Sample/Enzyme 
PK (0.4 mg/mL) PK (2 mg/mL) AMG (1.0 U) AMG (10.0 U) 
Volume (μL) 
Purified Compound NIL NIL NIL NIL 
PSK (2 mg/mL) NIL NIL NIL NIL 
PK (20 mg/mL) 5.0 25.0 NIL NIL 
AMG (45 U/mL) NIL NIL 4.50 45.0 
MilliQ Water 345.0 325.0 345.5 305.0 
Total Volume 350.0 
*Only subjected to the 2 hours incubation at 37°C but not heat deactivation. 
Table 13. Preparation of the preloads, ISPP-Rb and PSK without treatment with Proteinase K (PK) 
and α-amyloglucosidase (AMG). 
Sample/Enzyme 
ISPP-Rb* ISPP-Rb PSK* PSK 
Volume (μL) 
Purified Compound 300 300 NIL NIL 
PSK (2 mg/mL) NIL NIL 300 300 
PK (20 mg/mL) NIL NIL NIL NIL 
AMG (45 U/mL) NIL NIL NIL NIL 
MilliQ Water 50.0 50.0 50.0 50.0 
Total Volume 350.0 
*Only subjected to the 2 hours incubation at 37°C but not heat deactivation. 
For the second stage of the enzyme degradation experiment, whereby preliminary data 
from GC-MS analysis was obtained, the enzyme degradation assay was reassessed by repeating 
the use Proteinase K (PK) but not with α-amyloglucosidase (AMG). For the PK enzyme 
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degradation assay, the previously described protocol was used, but this time with a known 
mushroom sample concentration and a higher PK treatment concentration. Tables 14-15 depicts 
preparation of the sample-enzyme mixture for the enzyme degradation assay using PK. 
Table 14. Preparation of the treatment of ISPP-Rb, treated with 1 mg/mL of Proteinase K (PK). 
Sample/Enzyme 
Preload* Preload ISPP-Rb PK Control 
Volume (μL) 
ISPP-Rb (2 mg/mL) 150.0 150.0 150.0 NIL 
PK (20 mg/mL) NIL NIL 10.0 10.0 
MilliQ Water 50.0 50.0 40.0 190.0 
Total Volume 200.0 
*Only subjected to the 2 hours incubation at 37°C but not heat deactivation. 
Table 15. Preparation of the treatment of positive control (P. aurea) treated with 1 mg/mL of 
Proteinase K (PK). 
Sample/Enzyme 
Preload* Preload P. aurea PK Control 
Volume (μL) 
P. aurea (2 mg/mL) 150.0 150.0 150.0 NIL 
PK (20 mg/mL) NIL NIL 10.0 10.0 
MilliQ Water 50.0 50.0 40.0 190.0 
Total Volume 200.0 
*Only subjected to the 2 hours incubation at 37°C but not heat deactivation 
3.6.2 Enzyme Degradation Assay using α-L-Fucosidase and α-Galactosidase 
The second stage involved the use of α-L-Fucosidase (FCS) from bovine kidney (Sigma 
Aldrich) and α-Galactosidase (GAL) from green coffee beans (Sigma Aldrich). During this stage, 
the activity of PSK which was previously active had been lost and hence could not be used as a 
positive control. Polysaccharide samples from P. aurea were tested along with ISPP-Rb to see if 
the carbohydrate linkage was important for its immuno-stimulatory activity. 
For the FCS and GAL enzyme degradation assay, the experiment was first carried out for 
2 and 24 hours in the absence of a buffer, to ensure that the enzyme has sufficient time to react 
with the polysaccharide samples. The sample-enzyme mixture set up are as depicted in Tables 16-
18. All samples were incubated at 37°C for 2 or 24 hours, followed by heat deactivation at 80°C 
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for 20 min, with the exception of ISPP-Rb* and P. aurea*, which was only subjected to the 2 or 
24 hours incubation at 37°C, and not heat deactivation. After heat deactivation, the samples were 
stored at 4°C prior to addition to RAW 264.7 cells the following day. 
Table 16. Preparation of the treatment of ISPP-Rb and P. aurea with α-L-Fucosidase (FCS) and 
α-Galactosidase (GAL) in the absence or presence of 10 mM piperazine buffer (pH 5.5). 
Sample/Enzyme 
FCS (0.01 U) GAL (0.1 U) 
Volume (μL) 
Purified Compound (2 mg/mL) 150 150 
FCS (7.7 U/mL) 1.3 NIL 
GAL (47.3 U/mL) NIL 2.1 
MilliQ Water/Buffer (40 mM) 48.7 47.9 
Total Volume 200.0 
*Only subjected to the 2 or 24 hours incubation at 37°C but not heat deactivation. 
 
Table 17. Preparation of the negative control, water/buffer treated with α-L-Fucosidase (FCS) and 
α-Galactosidase (GAL). 
Sample/Enzyme 
FCS (0.01 U) GAL (0.1 U) 
Volume (μL) 
Purified Compound (2 mg/mL) NIL NIL 
FCS (7.7 U/mL) 1.3 NIL 
GAL (47.3 U/mL) NIL 2.1 
MilliQ Water/Buffer (40 mM) 198.7 197.9 
Total Volume 200.0 
 
Table 18. Preparation of the preloads, ISPP-Rb and P. aurea without treated with α-L-Fucosidase 
(FCS) and α-Galactosidase (GAL) in the absence or presence of 10 mM piperazine buffer (pH 5.5). 
Sample/Enzyme 
ISPP-Rb* ISPP-Rb P. aurea* P. aurea 
Volume (μL) 
Purified Compound (2 mg/mL) 150 150 150 150 
FCS (7.7 U/mL) NIL NIL NIL NIL 
GAL (47.3 U/mL) NIL NIL NIL NIL 
MilliQ Water/ Buffer (40 mM) 50.0 50.0 50.0 50.0 
Total Volume 200.0 
         *Only subjected to the 2 or 24 hours incubation at 37°C but not heat deactivation. 
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3.6.3 Glycoprotein Stain using SDS-PAGE Gel on ISPP-Rb Treated with Enzymes α-L-
Fucosidase and α-Galactosidase 
Due to insignificant changes in immuno-stimulatory activity of the mushroom samples 
treated with FCS and GAL (see Figures 24-26 in section 3.21), the mushroom samples treated 
with both the enzymes were run on a SDS PAGE gel to visualize any changes in band or smearing 
pattern as compared to their respective preloads, which were not treated by the enzymes. If a 
different band or smearing pattern was observed amongst the treated and untreated sample, this 
will confirm that the enzyme was actually active, and not because of the insufficient amount of 
enzyme used in the experiment. The samples were treated as previously described in Tables 16-
18 but at a lower volume. Tables 19-20 illustrates the preparation of the sample-enzyme mixture 
for the enzyme degradation assay using both FCS and GAL. 
Table 19. Preparation of the treatment of ISPP-Rb and P. aurea with α-L-Fucosidase (FCS) and 
α-Galactosidase (GAL). 
Sample/Enzyme 
Preload FCS (0.01 U) GAL (0.1 U) 
Volume (μL) 
Purified Compound (20 mg/mL) 15.0 15.0 15.0 
FCS (7.7 U/mL) NIL 1.3 NIL 
GAL (47.3 U/mL) NIL NIL 2.1 
MilliQ Water 5.0 3.7 2.9 
Total Volume 20.0 
 
Table 20. Preparation of the negative and enzyme controls treated with α-L-Fucosidase (FCS) and 
α-Galactosidase (GAL). 
Sample/Enzyme 
Water FCS Control GAL Control 
Volume (μL) 
Purified Compound (20 mg/mL) NIL NIL NIL 
FCS (7.7 U/mL) NIL 1.3 NIL 
GAL (47.3 U/mL) NIL NIL 2.1 
MilliQ Water 20.0 18.7 17.9 
Total Volume 20.0 
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The above mixtures were incubated at 37°C for 2 hours prior to heat deactivation at 80°C 
for 20 min and cooling on ice. The samples were then pulsed using a bench top centrifuge to spin 
down the condensate form at the top of the Eppendorf tubes. A total of 14 μL of each sample was 
mixed with 3 μL of dye (95% dye and 5% β-mercaptoethanol) and heated at 95°C for 10 min 
followed by pulsing with a bench top centrifuge to spin down the condensate formed at the top of 
the Eppendorf tubes. A total of 15 μL (approximately 200 μg of mushroom sample) and 5 μL of 
protein ladder were loaded into a 10% SDS PAGE gel which was prepared based on Table 21 and 
ran for approximately 45 min at 200 mV. 
 
Table 21. Preparation mixture for 10% SDS PAGE gel. 
Components Resolving Gel Stacking Gel 
30% Polyacrylamide 2.66 mL 0.48 mL 
4x SDS Buffer 2.00 mL (pH 8.8) 0.45 mL (pH 6.8) 
MilliQ Water 3.34 mL 1.77 mL 
TEMED 4.8 μL 3 μL 
20% APS 16 μL 7.5 μL 
 
 The gel was then stained using PierceTM Glycoprotein Staining Kit (Thermo Scientific) 
based on the manufacturer’s protocol. The gel was first immersed in 100 mL of 50% methanol for 
30 min to allow proper fixation. The gel was the washed twice with 100 mL of 3% acetic acid, 
each for 10 min with gentle shaking. Following that, the gel was then transferred to a 25 mL 
oxidizing solution and gently agitated over a shaker for 15 min. The gel was then subjected to 
washing with 100 mL of 3% acetic acid three times, each for 5 min over gently shaking. Next, the 
gel was then stained with 25 mL of Glycoprotein Staining Reagent and gently agitated. After 15 
min, the gel was then transferred to 25 mL of reducing solution and gently shaken for another 15 
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min prior to extensive washing with 3% acetic acid and MilliQ water. Upon complete washing, 
the gel was visualized using a gel viewer machine (FluoChem Q, ProteinSimple). 
3.7 Monosaccharide Content Analysis of ISPP-Rb using GC-FID 
The mushroom polysaccharide sample (ISPP-Rb) was sent to Dr. Peter Cheung’s lab at the 
Chinese University of Hong Kong (CUHK) and the monosaccharide contents were analyzed by 
Dr. Maggie Li. 
3.8 Carbohydrate Linkage Analysis of ISPP-Rb using GC-MS 
Mushroom polysaccharide sample (ISPP-Rb) was sent to Dr. Peter Cheung’s lab at the 
Chinese University of Hong Kong (CUHK) and the carbohydrate linkages were analyzed by Dr. 
Maggie Li. 
3.9 Determining the Presence of a Triple Helix Structure in ISPP-Rb Using Congo Red 
Colorimetric Assay 
3.9.1 Optimizing a Suitable Congo Red Concentration for Absorbance Visibility 
The Congo red colorimetric assay utilizes the ability of triple helix polysaccharides to form 
a complex with Congo red through hydrogen bonding and/or hydrophobic interactions when mixed 
with dilute alkaline solutions, which will result in a shift in the complex’s maximum absorption 
compared to the blank, i.e. Congo red solution (Smiderle et al., 2014). The assay was adapted and 
modified from Wang et al. (2013) and Smiderle et al. (2014). A 10 mM Congo red stock solution 
was prepared by dissolving the measured powder in MilliQ water. The stock was further diluted 
to form a 0.5, 1.0 and 5.0 mM Congo red stock for optimization steps. Four different Congo red 
concentrations were tested against six NaOH concentrations in order to search for an optimum 
absorbance profile. Tables 22-25 shows the preparation of the various Congo red-NaOH mixture. 
The Congo red concentration with the best absorbance visibility was selected for subsequent 
experiments. 
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Table 22. Preparation of 50 μM Congo Red in various NaOH concentrations. 
Final NaOH 
Concentration (M) 
Congo Red Final Concentration 50 μM 
Final Volume 
(μL) 
1M NaOH 
(μL) 
MilliQ Water 
(μL) 
0.5 mM Congo 
Red (μL) 
0 180 0 
20 200 
0.05 170 10 
0.10 160 20 
0.20 140 40 
0.30 120 60 
0.40 0 80 
 
Table 23. Preparation of 100 μM Congo Red in various NaOH concentrations. 
Final NaOH 
Concentration (M) 
Congo Red Final Concentration 100 μM 
Final Volume 
(μL) 
1M NaOH 
(μL) 
MilliQ Water 
(μL) 
1 mM Congo 
Red (μL) 
0 180 0 
20 200 
0.05 170 10 
0.10 160 20 
0.20 140 40 
0.30 120 60 
0.40 0 80 
 
Table 24. Preparation of 500 μM Congo Red in various NaOH concentrations. 
Final NaOH 
Concentration (M) 
Congo Red Final Concentration 500 μM 
Final Volume 
(μL) 
1M NaOH 
(μL) 
MilliQ Water 
(μL) 
5 mM Congo 
Red (μL) 
0 180 0 
20 200 
0.05 170 10 
0.10 160 20 
0.20 140 40 
0.30 120 60 
0.40 0 80 
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Table 25. Preparation of 1000 μM Congo Red in various NaOH concentrations. 
Final NaOH 
Concentration (M) 
Congo Red Final Concentration 1000 μM 
Final Volume 
(μL) 
1M NaOH 
(μL) 
MilliQ Water 
(μL) 
10 mM Congo 
Red (μL) 
0 180 0 
20 200 
0.05 170 10 
0.10 160 20 
0.20 140 40 
0.30 120 60 
0.40 0 80 
 
3.9.2 Analysis of the Presence of a Triple Helix Structure in ISPP-Rb 
Upon successful determination of the optimum Congo red concentration, the triple helix 
analysis of the polysaccharide samples was performed. The samples used were ISPP-Rb, P. aurea 
sample and Echinodontium. tinctorium (Ellis & Everh.) Ellis & Everh. sample (provided by Ms. 
Mehreen Zeb, a graduate student in Dr. Lee’s Lab). The controls selected were PSK and Dextran 
(410 kDa). A 2 mg/mL solution of all samples and controls were prepared for analysis. Generally, 
samples and controls (final concentration 1 mg/mL) will be treated with diluted NaOH solution (0, 
0.05, 0.1, 0.2, 0.3, and 0.4M) and allowed to react with 100 μM of Congo red solution prior to 
reading the absorbance spectrum from 450-550 nm. The reaction mixture is as shown in Table 26. 
Table 26. Treatment of mushroom samples with various NaOH concentrations and 100 μM Congo 
red solution. 
Final NaOH 
Concentration 
(M) 
Congo Red Final Concentration 100 μM 
Final 
Volume (μL) 
1M NaOH 
(μL) 
MilliQ 
Water (μL) 
2 mg/mL 
Sample (μL) 
1 mM Congo 
Red (μL) 
0 80 0 
100 20 200 
0.05 70 10 
0.10 60 20 
0.20 40 40 
0.30 20 60 
0.40 0 80 
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3.10 Determination of the Presence of O-Glycosidic Bond in the Immuno-Stimulatory 
Compound of ISPP-Rb using the β-Elimination Assay 
The carbohydrate-peptide linkages of ISPP-Rb were analyzed using the β-elimination 
assay described by Wu et al. (2015) with modification. The first step was to optimize the reaction 
time required. Reaction times of 2, 4, 10, 12 and 16 hours were used on an immuno-stimulatory 
polysaccharide purified from P. aurea due to the abundant material available. Generally, a total of 
100 μL of 2 mg/mL P. aurea sample were mixed with 100 μL 0.2 mol/L NaOH containing either 
2.0 M or 4.0 M NaBH4 (in duplicates) and incubated in the AccublockTM Digital Dry Bath (Labnet) 
at 45°C for 2 hours. After the incubation period, 100 μL of the sample mixture was transferred to 
a 96-wells UV plate and the absorbance read from 230 - 300 nm against the blank solutions (0.1 
M NaOH with 1.0 M or 2.0 M NaBH4 and water) using SYNERGY 2 (Biotek®). In the presence 
of O-glycosidic bonds, an increase in absorbance at 240 nm should be observed. The sample that 
failed to show an increase in absorbance at 240 nm will serve as the negative control. Upon 
confirming the optimum reaction time, the experiment proceeded with purified bioactive 
compounds, i.e. ISPP-Rb, immuno-stimulatory polysaccharide from E. tinctorium and a positive 
control, aggrecan (2 mg/mL). 
Another β-elimination assay without the use of the reducing agent NaBH4 was also carried 
out based on a protocol established by Yi et al. (2011) with modification. A total of 100 μL of 2 
mg/mL mushroom samples (ISPP-Rb, P. aurea, and E. tinctorium) and positive control, Aggrecan 
(2 mg/mL) were mixed with 100 μL 0.2 mol/L NaOH (in duplicates) and incubated in the 
AccublockTM Digital Dry Bath (Labnet) at 45°C for 2 hours. After the incubation period, 100 μL 
of the sample mixture was transferred to a 96-wells UV plate and the absorbance was read from 
230 - 300 nm against the blank solution using SYNERGY 2 (Biotek®). In the presence of O-
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glycosidic bonds, an increase in absorbance at 240 nm should be observed. The sample that failed 
to show an increase in absorbance at 240 nm served as the negative control. 
3.11 Analysis of Cytokines Induced by ISPP-Rb in RAW 264.7 Cells 
The ISPP-Rb fraction that stimulated the highest TNF-α production in RAW 264.7 cells as 
depicted by the data from ELISA as well with a negative control (RAW 264.7 cells treated with 
150 mM NaCl) were selected for further analysis on the types of cytokines and chemokines that 
could be induced. A total of 100 μL of the supernatant collected post-treatment with the selected 
fraction or with 150 mM NaCl serving as a blank were each aliquoted into a 0.5 mL Eppendorf 
Safe-Lock TubesTM (Eppendorf) and sent to Eve Technologies (Calgary, AB) for analysis using 
the Mouse Cytokine 32-Plex Discovery Assay. Analysis of the cytokine induced will allow for a 
better understanding on the types of immune responses triggered by the immuno-stimulatory 
compound from R. badius. 
3.12 Analysis of Phagocytic Activity of RAW 264.7 Cells Treated with ISPP-Rb using 
Neutral Red Colorimetric Assay 
3.12.1 Investigating a Suitable Cell Media Requirement and LPS Concentration 
The neutral red assay was adopted and modified from Teng et al. (2015) and  Zheng et al. 
(2017). The first approach was to determine the medium requirement for the assay. A total of 100 
μL containing 10,000 RAW 264.7 cells in DMEM with and without FBS were seeded in 96-wells 
plate and left to adhere to the bottom of the wells for 4 hours. The cells were then treated with LPS 
(100, 250, and 500 ng/mL) and left to incubate at 37°C under 5% CO2 for 24 hours. The 
supernatants of the cells were then removed and the cells were washed once with 200 μL of PBS 
prior to adding 100 μL of 0.075% Neutral Red dissolved in DMEM with and without FBS. The 
cells were then left to incubate at 37°C under 5% CO2. After 3 hours, the neutral red solution was 
removed and the cells were washed twice with 200 μL of PBS each to remove any excess stains 
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prior to adding 100 μL of lysis buffer (Acetic Acid:Ethanol, 1:1). The plate was vortexed at 800 
rpm for 30 sec using a Micro Plate Shaker (VWR®) prior to reading the absorbance value at 540 
nm using SYNERGY 2 (BIOTEK®) machine. 
3.12.2 Optimizing a Suitable Mushroom Sample Dose for Cell Treatment 
The protocol stated in section 3.12.1 was adopted for use, with DMEM without FBS being 
the media of choice. LPS (250 and 500 ng/mL), along with and ISPP-Rb and P. aurea samples (all 
at 0.5, 1.0, 2.5, 5.0, 10, 25, 50, 100, and 250 μg/mL) were treated to RAW 264.7 cells. 
3.12.3 Optimizing the Neutral Red Concentration for Absorbance Visibility 
With inconsistencies from the previous optimization steps, the next approach was to 
modify the Neutral Red dye concentration with the rationale of seeing a higher absorbance reading 
and also the dissolving solvent. Three concentrations of 0.0375, 0.075 and 0.15% Neutral Red dye 
dissolved in MilliQ water were tested on cells. The protocol used was similar to that in section 
3.12.1, but with modification to the Neutral Red addition step. Generally, 100 μL containing 
10,000 RAW 264.7 cells in DMEM with and without FBS were seeded in 96-well plate and left to 
adhere to the bottom of the wells for 4 hours. The cells were then treated with LPS (250 and 500 
ng/mL) and left to incubate at 37°C under 5% CO2 for 24 hours. The supernatants of the cells were 
then removed and the cells were washed once with 200 μL of PBS prior to adding 100 μL of 
DMEM without FBS followed by the addition of the aforementioned Neutral Red solution. The 
cells were then left to incubate at 37°C under 5% CO2. After 3 hours, the neutral red solution was 
removed and the cells were washed twice with 200 μL of PBS each to remove any excess stains 
prior to adding 100 μL of lysis buffer (Acetic Acid:Ethanol, 1:1). The plate was vortexed at 800 
rpm for 30 sec using a Micro Plate Shaker (VWR®) prior to reading the absorbance value at 540 
nm using SYNERGY 2 (BIOTEK®). 
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3.13 Statistical Analysis 
Statistical analysis using One Way ANOVA (Tukey Test) or Student t-Test was performed 
in Graph Prism Version 6.0, whereby the data shown are expressed in mean ± standard deviation 
(SD). 
Results and Discussion 
3.14 Relative Carbohydrate and Protein Content of BRLI_#86_E3_LH20, 
BRLI_#86_E3_LH20_DEAE and BRLI_#150_E3_DEAE_Sephacryl (ISPP-Rb) 
Carbohydrate content analysis was initially carried out on the Post LH20 fractions of the 
water extracts, E3 of mushroom #86. Figure 16 depicts the relative carbohydrate content and their 
respective immuno-stimulatory activity of the Post LH20 fractions from the 400 mL LH20 column. 
 
Figure 16. Carbohydrate content and TNF-α production of the Post LH20 fractions of E3 from 
mushroom #86 eluted off the 400 mL LH20 column. Data presented is a representation of three 
separate experiments. 
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 It can be observed in Figure 16 that there are two carbohydrate peaks, where the first 
carbohydrate peak corresponds to the first immuno-stimulatory activity peak. This suggests that 
the bioactive compound could be a polysaccharide. Unfortunately, the relative protein content for 
the Post LH20 fractions of E3 from mushroom #86 eluted off the 400 mL LH20 column and was 
not determined at that time. Upon completion of the purification step using LH20 SephadexTM, the 
semi-purified fractions were then subjected to purification using DEAE SephadexTM A-50. The 
purification optimization data are as presented in section 2.10 in Chapter 2. According to Figure 
16, it can be observed that there were two carbohydrate peaks eluted from the LH20 columns, 
however the immuno-stimulatory activity only corresponded with the first carbohydrate peak. 
Hence, a carbohydrate and protein quantification assay were performed on the flow through and 
elution collected from the DEAE column. Figures 17a and 17b depict the carbohydrate and protein 
content of the flow through and elution collected off the DEAE column respectively. 
          
Figure 17. (a) Carbohydrate content and (b) protein content of the Post LH20-DEAE fractions 
(flow through and elution) collected when 20 mg of E3 from mushroom #86 was loaded into the 
75 mL DEAE column. Data presented is an average from two independent experiments (n=2). 
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The data above confirms the presence of both carbohydrate and protein components in the 
active compound, whereby the protein content of the Post LH20 eluted active fractions could not 
be determined. Furthermore, it also suggests that the DEAE purification step was indeed removing 
impurities as depicted by the presence of carbohydrate and protein content in the flow through, 
which could be from the second carbohydrate observed in Figure 16 which did not contribute to 
any immuno-stimulatory activity.  
 Following the completion of the DEAE purification of the water extracts (E3 of mushroom 
#86), the third purification step was using the Sephacryl S500 column. Unfortunately, due to 
contamination issues as described in section 2.11 in Chapter 2, the relative carbohydrate and 
protein contents were not determined. The purification step had to be redone with a new batch of 
R. badius (mushroom #150), whereby the activity in the water extracts, E3 has been confirmed as 
presented in Figure 4b in section 2.8 of Chapter 2. With the rationale that the DEAE SephadexTM 
A-50 was able to remove the inactive carbohydrates and proteins (see Figures 17a-b), and also 
the inefficiency of the SephadexTM LH20 due to its low exclusion limit of 4-5 kDa, it was decided 
that the initial first step of purification using SephadexTM LH20 was no longer necessary and hence 
omitted. Therefore, the purification of the E3 of mushroom #150 was subjected directly to DEAE 
SephadexTM followed by Sephacryl S500. Figures 18a and 18b shows the relative carbohydrate 
and protein of the fractions eluted off the Hi-Prep Sephacryl S500 column. 
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Figure 18. (a) Carbohydrate content of the Post DEAE-Sephacryl fractions from mushroom #150 
collected using Hi-Prep Sephacryl S500 column; (b) Protein content of the Post DEAE-Sephacryl 
fractions from Mushroom #150 collected using Hi-Prep Sephacryl S500 column. Data presented 
are each a representation from three separate experiments. 
 
 Based on Figures 18a-b, in Post-DEAE SephadexTM A-50 column, the second 
carbohydrate and/or protein peak that were previously seen using the SephadexTM LH20 column 
was no longer detected. This is consistent with my previous hypothesis that DEAE SephadexTM 
column was able to remove inactive carbohydrate and protein components. With the higher 
resolution Hi-Prep Sephacryl S500 column (exclusion limit of 40-2000 kDa), the active compound 
is expected to be better separated as compared to using the crude SephadexTM LH20 column. 
Although the active compound, when previously separated using SephadexTM LH20 column, 
showed that the immuno-stimulatory activity peak corresponded to the carbohydrate peak (see 
Figure 16), it was no longer the case after passing through the high resolution Sephacryl S500 
column. Despite that, there was still a small amount of protein and carbohydrate detected within 
the active region of the fractions collected, which still suggests that the active compound could be 
a polysaccharide-protein mixture. 
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3.15 Total Carbohydrate and Protein Content of ISPP-Rb 
In order to investigate if the active compound has any carbohydrate or protein content, due 
to their relative low amount as depicted in Figures 18a-b, the total carbohydrate and protein 
content of ISPP-Rb are as stated below in Table 27. It was confirmed that the active compound 
contains both carbohydrate and protein, with a total carbohydrate and protein content of 
approximately 57.4% and 16.7% respectively, with the remaining 25.9% being unknown. This 
could possibly be due to the presence of impurities or the possibility of any inorganic binding 
metals or organic matter bound to the active compound. 
Table 27. Total carbohydrate and protein content of the purified bioactive compound from the 
water extracts, E3 of mushroom #150. Data presented are of two independent experiments (n=2). 
Mushroom Sample Total Carbohydrate 
Content (% w/w) 
Total Protein Content 
(% w/w) 
ISPP-Rb 57.4 ± 2.1 16.7 ± 1.7 
Note: The carbohydrate content as determined using GC-FID while the protein content was 
determined using BCA assay. 
 
3.16 Size Estimation of ISPP-Rb 
Since the immuno-stimulatory compound was suggested to be a polysaccharide-protein 
complex, it was important to estimate its approximate size. With the use of dextran standards, the 
molecular size of the ISPP-Rb was estimated to be approximately 400 kDa. Figure 19 depicts the 
dextran standards and immuno-stimulatory activity of the eluted fractions from Sephacryl S500. 
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Figure 19. Immuno-stimulatory activity and size of the Post DEAE-Sephacryl fractions of E3 from 
mushroom #150 eluted off the Hi-Prep Sephacryl S500 column. Data presented is a representation 
from three separate experiments. The numbers indicate the dextran standards in kDa. 
 
3.17 Total β-Glucan Content of ISPP-Rb 
With the data in Table 27 from section 3.15 confirming the presence of carbohydrate in 
ISPP-Rb, it was thought that the active compound could possibly be a β-glucan. β-D-glucans are 
made up of linear unbranched polysaccharides of β-D-glucose which have been reported to possess 
immuno-modulating properties and have attracted a wide interest especially after the discovery of 
glucan receptors responsible for the innate immune response on the cell surface of various immune 
cells (Vannucci et al., 2013). Most importantly, fungi are the main source of β-D-glucans, which 
usually originates from the fungal cell wall (Novak & Vetvicka, 2008). Taken together, I decided 
to quantify the amount of β-glucan present in my immuno-stimulatory compound as described in 
section 3.5. Table 28 depicts the amount of glucan present in ISPP-Rb. 
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Table 28. Glucan content of the purified active compound from the water extracts (E3) of 
mushroom #150. Data presented are from two independent experiments (n=2). 
Mushroom Sample Total Glucan 
(% w/w) 
Total α-Glucan 
(% w/w) 
Total β-Glucan  
(% w/w) 
ISPP-Rb 0.48 ± 0.03 0.20 ± 0.05 0.28 ± 0.08 
P. aurea Polysaccharide 22.0 ± 0.4 3.1 ± 1.1 18.9 ± 0.8 
Yeast Control 45.9 ± 2.7 0.5 ± 0.0 45.5 ± 2.7 
 
 Interestingly, extremely low level or no β-glucan was detected in ISPP-Rb, despite reports 
claiming how frequent these sugar polymers are found in fungal tissues. Hence, it can be concluded 
that the immuno-stimulatory activity of ISPP-Rb is not due to a  β-glucan polymer. 
3.18 Monosaccharide Content of ISPP-Rb 
 With the absence or extremely low abundance of β-glucans in ISPP-Rb, it was thought that 
a further investigation in the monosaccharides content present in the active compound would 
provide a better understanding regarding its chemical characteristic. The monosaccharide content 
analysis of ISPP-Rb was performed by Dr. Maggie Li in Dr. Peter Cheung’s lab at CUHK using 
GC-FID (Gas Chromatography-Flame Ionization Detector). According to the preliminary data 
obtained from GC-FID analysis, it was determined that approximately 45% of the active 
compound was made up of galactose, while glucose accounted for nearly 40% of the total 
monosaccharides present, with mannose, xylose and fucose each accounting for less than 10% 
each. Table 29 depicts the types of monosaccharide present in the polysaccharide of the immuno-
stimulatory compound from mushroom #150.  
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Table 29. Monosaccharide composition of the purified active compound from the water extracts 
(E3) of mushroom #150. Data presented are an average from two independent experiments (n=2). 
Monosaccharide Percentage (% w/w) 
Fucose 3.8 ± 0.3 
Xylose 1.3 ± 0.1 
Mannose 9.4 ± 1.8 
Glucose 39.8 ± 0.1 
Galactose 45.8 ± 1.6 
Total 100 
 
 Interestingly, despite the lack of β-glucan present in ISPP-Rb, around 40% of glucose was 
detected in GC-FID analysis. This indicates the absence of 1,3-Glucose and 1,6-Glucose, which 
are the carbohydrate linkages present in β-glucan, but also suggests the possible presence of other 
glucose linkages.  
3.19 Carbohydrate Linkages of ISPP-Rb 
The carbohydrate linkages of ISPP-Rb was performed by Dr. Maggie Li in Dr. Peter 
Cheung’s lab at CUHK using GC-MS. Table 30 depicts the types of carbohydrate linkages present 
in the polysaccharide of the immuno-stimulatory compound of mushroom #150. 
Table 30. Types of carbohydrate linkages of the purified active compound from the water extracts 
(E3) of Mushroom #150. Degree of branching (DB)* =0.71. *DB = (NT + NB)/(NT+ NB+ NL), 
where NT, NB, NL are the total numbers of the terminal residues, branching residues, and linear 
residues respectively. Data presented is a representation of one single experiment. 
 
Carbohydrate Linkages Percentage (% w/w) 
Terminal Fucose 8.2 
Terminal Glucose 6.0 
Terminal Galactose 16.8 
1,6-Mannose 16.3 
1,6-Galactose 13.0 
1,2,6-Glucose 39.7 
Total 100 
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According to the preliminary data obtained from GC-MS, the 1,2,6-Glucose linkage was 
found to make up approximately 40% of all the linkages, which resulted in the high degree of 
branching (0.71). This was followed by terminal galactose, (1 → 6)-mannose (Man) and (1 →6)-
galactose (Gal), each accounting for 16.8%, 16.3% and 13.0% respectively. Both terminal glucose 
and fucose only accounted for less than 10% each. This result is consistent with the data obtained 
in Tables 28 and 29 (section 3.17 and section 3.18). As previously mentioned, ISPP-Rb did not 
contain any β-glucan, however glucose was detected, which can now be explained as the glucose 
detected was derived from the presence of terminal glucose and the (1 → 2,6)-glucose (Glc) 
linkages. By comparing Tables 29 and 30, it can be seen that all the monosaccharides detected 
were all part of the carbohydrate linkages resolved, except for xylose, which is likely due to its 
relatively low amount, making it undetectable during the linkage analysis using GC-MS. 
3.20 Helical Conformational Analysis of ISPP-Rb 
 It has been reported that the helical conformation of polysaccharides play an important role 
in determining its immuno-stimulatory potency, generally with triple helix structures being the 
more potent compared to that of single helices (Meng et al., 2016). Hence, the attempt was to 
investigate the possible helical conformation of ISPP-Rb as described in section 3.9. Figure 20a 
illustrates the results of an experiment to optimize the concentration of Congo Red. Figure 20b 
shows the result on the effect of NaOH on the binding of polysaccharide samples to Congo red. 
According to Smiderle et al. (2014), triple helical polysaccharides will form a complex with Congo 
red in diluted NaOH solutions as a result of the stabilization between the polysaccharide and the 
dye molecule via strong hydrogen bonding along with possible hydrophobic interactions. Such a 
phenomenon can be detected by observing a change in the wavelength where absorbance is at 
maximum (λMax) of the Congo red spectrum.  
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Figure 20. UV spectra (400-600 nm) at an interval of 10 nm of (a) Congo red solution at 50, 100, 
500, and 1000 μM; (b) the polysaccharide sample treated with 0.1 M NaOH and 100 μM Congo 
red. Data shown is from (a) one experiment, or (b) an average of two independent experiments 
(n=2). 
 
Based on Figure 20a, 100 μM Congo red showed a peak absorbance reading at 
approximately 1.0, which allows for visible changes during absorbance changes (increase or 
decrease). On the other hand, Congo red concentrations of 500 and 1000 μM experienced an 
overexpression of absorbance reading which resembles too high a concentration for the assay and 
was hence omitted. Furthermore, the concentration of Congo red tested in this particular study 
have been reported to range from 10 – 100 μM (Palacios et al., 2012; Smiderle et al., 2014). Hence, 
selecting 100 μM Congo red as the working concentration is therefore a good rationale. 
Unfortunately, despite obtaining a suitable working Congo red concentration, none of the samples 
and controls tested had any visible shift in the maximum absorbance at 0.1 M NaOH (Figure 20b) 
and the other NaOH concentration tested (data not shown). Based on Ogawa et al. (1972), the 
Congo red had only previously been reported to form a complex with β-1,3- and β-1,4- glucans 
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under dilute NaOH conditions. Surprisingly then, PSK, a protein bound β-1,3- and 1,6-glucan 
failed to show any shift in maximum absorbance. This could be due to the interference of the 
protein molecule attached to it. Chan et al. (2009) explained that despite PSK having β-glucan, the 
fact that a protein molecule is bounded to it makes it different from a pure β-glucan. Without a 
working positive control, the results obtained were inconclusive. 
3.21 Effect of Enzyme Treated ISPP-Rb on Its Bioactivity 
The enzyme assays were carried out in two phases, with the first phase being done prior to 
the linkage analysis, while the second phase was performed after obtaining the carbohydrate 
linkage data. The rationale of this study is to treat the active compound with certain enzymes to 
see if the enzyme was capable of affecting the active compounds immuno-stimulatory activity. If 
the immuno-stimulatory activity of the compound is decreased after enzyme digestion, that would 
be indicative of the significant role played by the digested portion (i.e. protein or polysaccharide). 
The first phase of the enzyme digestion experiment was carried out on ISPP-Rb using Proteinase 
K (PK) and α-amyloglucosidase (AMG). Figures 21a and 21b show the PK treatment on ISPP-
Rb and PSK respectively; while Figures 22a and 22b illustrate the AMG treatment on ISPP-Rb 
and PSK respectively. 
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Figure 21. The effect of Proteinase K (PK) treatment on the immuno-stimulatory activity of (a) 
ISPP-Rb and (b) positive control, PSK. The symbol (*) indicates heated at 80°C for 20 min. Data 
presented are a representative of two separate experiments. Statistical analysis was assessed using 
One-Way ANOVA (Tukey Test) with N.S (P > 0.05), *** (P < 0.05). 
 
     
Figure 22. The effect of α-amyloglucosidase (AMG) treatment on the immuno-stimulatory 
activity of (a) ISPP-Rb and (b) positive control, PSK. The symbol (*) indicates heated at 80°C for 
20 min. Data presented are a representative of two separate experiments. Statistical analysis was 
assessed using One-Way ANOVA (Tukey Test) with N.S (P > 0.05), *** (P < 0.05). 
 
 Based on Figures 21a-b, it can be seen that at 0.4 mg/mL of PK treatment, the immuno-
stimulatory activity of ISPP-Rb and positive control PSK was lost as compared to the initial 
preload (unheated ISPP-Rb and PSK), indicating that the protein component is important for their 
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bioactivity. However, treatment of PK at 2 mg/mL on PSK had no effect against its immuno-
stimulatory activity, which is likely due to the high concentration of glycerol present in the PK 
stock solution, inhibiting the enzyme activity of PK. On the other hand, treatment with AMG as 
depicted in Figures 22a-b, resulted in an increase in immuno-stimulatory activity as compared to 
their respective preloads (unheated ISPP-Rb and PSK). AMG functions by cleaving α-1,3-, 1,4- 
and 1,6-glucosidic linkages, and despite ISPP-Rb not having any detectable quantities of the 
aforementioned three linkages, these linkages could have been of very minute quantities derived 
from the presence of the terminal glucose, which could be directly linked to a glucose from the 
1,2,6-glucose linkage present in high amounts. Hence, the stimulation observed could be a 
consequence of the digestion of the compound to a more potent derivative of the previous active 
compound. The possibility that AMG itself being immuno-stimulatory is less likely because the 
enzyme alone (control) did not show any significant immuno-stimulation. Other than the effect of 
enzymes, it can also be deduced that the active compound is heat sensitive, as depicted by the 
decrease in activity upon heat treatment during enzyme deactivation. 
 To further confirm the role of the protein component in the bioactivity of ISPP-Rb and its 
sensitivity towards heat, the experiment was repeated. The results shown in Figures 23a-b 
included a different positive control (P. aurea sample) and a known concentration of ISPP-Rb as 
compared to the previously unknown concentration which was the reason behind the lower 
immuno-stimulatory activity observed. The final concentration of both mushroom samples was 
1.5 mg/mL and the treatment was 1 mg/mL of the enzyme PK. Enzyme treated mushroom samples 
were then treated on RAW 264.7 cells at a final concentration of 0.375 mg/mL. 
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Figure 23. The effect of Proteinase K (PK) treatment on the immuno-stimulatory activity of (a) 
ISPP-Rb and (b) positive control, P. aurea polysaccharide sample. The final concentration of both 
samples was 1.5 mg/mL and treated with 1 mg/mL of the enzyme PK. Enzyme treated mushroom 
samples were then treated on RAW 264.7 cells at a final concentration of 0.375 mg/mL. The 
symbol (*) indicates heated at 80°C for 20 minutes. Data presented is the mean ± SD from three 
independent experiments (n=3). Statistical analysis was assessed using One-Way ANOVA (Tukey 
Test) with N.S (P > 0.05), *** (P < 0.05). 
 
Unfortunately, at the time of this experiment the immuno-stimulatory activity of Krestin 
(PSK) could not be observed, possibly due to degradation, and hence the results were not included 
in Figure 23. However, previous experiments done by Ms. Vicky Myhre in Dr. Lee’s lab have 
shown that the immuno-stimulatory activity of her P. aurea samples were also reduced by PK 
treatment (data not shown), and hence could serve as a positive control. With the above 
confirmation, the deduction that ISPP-Rb is relatively heat stable and the requirement of the 
protein component for its immuno-stimulatory activity was confirmed and validated.  
The second phase involved the use of α-L-Fucosidase (FCS) and α-Galactosidase (GAL). 
Figures 24a and 24b depict the FCS and GAL treatment respectively on P.aurea sample and ISPP-
Rb for 2 hours, while Figures 25a and 25b illustrate the FCS and GAL treatment on P.aurea 
sample and ISPP-Rb for 24 hours respectively. 
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Figure 24. The effect of α-L-Fucosidase (FCS) and α-Galactosidase (GAL) treatment on the 
immuno-stimulatory activity of (a) P. aurea and (b) ISPP-Rb for 2 hours in the absence of a 
buffering system. The symbol (*) indicates heated at 80°C for 20 minutes. Data presented is the 
mean ± SD from a single experiment. Statistical analysis was assessed using One-Way ANOVA 
(Tukey Test) with N.S (P > 0.05), *** (P < 0.05). 
 
   
Figure 25. The effect of α-L-Fucosidase (FCS) and α-Galactosidase (GAL) treatment on the 
immuno-stimulatory activity of (a) P. aurea and (b) ISPP-Rb for 24 hours in the absence of a 
buffering system. The symbol (*) indicates heated at 80°C for 20 minutes. Data presented is the 
mean ± SD from a single experiment. Statistical analysis was assessed using One-Way ANOVA 
(Tukey Test) with N.S (P > 0.05), *** (P < 0.05). 
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Based on Figures 24a-b and 25a-b, there was no significant change in the immuno-
stimulatory activity of the active compounds treated with the enzymes FCS and GAL at both 2 and 
24 hours. This could be due to the absence of a proper buffering system as the manufacturer (Sigma 
Aldrich) states that the optimum pH for both enzymes should be within a pH range of 5-6. Hence, 
a second assay was performed in the presence of a 10 mM piperazine buffer at pH 5.5 for only 24 
hours as there was no effect observed on the preloads when incubated at 37°C for 2 or 24 hours in 
the absence of a buffer. Unfortunately, with the addition of a buffer system, there was also no 
significant change observed on the immuno-stimulatory activity of both polysaccharide samples 
when treated with FCS and GAL (Figures 26a-b). 
   
Figure 26. The effect of α-L-Fucosidase (FCS) and α-Galactosidase (GAL) treatment on the 
immuno-stimulatory activity of (a) P. aurea and (b) ISPP-Rb for 24 hours in the presence of 10 
mM Piperazine buffer at pH 5.5. The symbol (*) indicates heated at 80°C for 20 minutes. Data 
presented is the mean ± SD from a single experiment. Statistical analysis was assessed using One-
Way ANOVA (Tukey Test) with N.S (P > 0.05), *** (P < 0.05). 
 
It is unlikely that the enzymes used were insufficient as they were calculated to be in excess 
relative to the amount of samples used. In addition to the above experiments, the mushroom 
polysaccharide samples treated/not treated with enzymes FCS and GAL were run on a SDS PAGE 
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gel and visualized using a glycoprotein staining kit. The rationale behind this experiment was 
intended to check if the enzyme had already cleaved the polysaccharide, in hope that a difference 
in the band or smearing pattern will be observed between the enzyme-treated and non-treated 
mushroom samples. Such a difference will suggest that the absence of suppression in the immuno-
stimulatory activity of the mushroom samples treated with enzymes as compared to their respective 
preloads (enzyme-untreated samples) were not due to the lack of enzyme concentration, but due 
to the non-importance of the specific carbohydrate bonds towards the active compound’s immuno-
stimulatory activity. Figure 27 depicts the band images of P. aurea sample and my ISPP-Rb on 
the SDS PAGE gel stained with a glycoprotein staining kit respectively. 
 
Figure 27. The effect of α-L-Fucosidase (FCS) and α-Galactosidase (GAL) treatment on the 
relative size of P. aurea sample and ISPP-Rb for 2 hours in the absence of a buffering system. 
Data presented is a representative of two separate experiments. 
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 Based on Figure 27, it can be clearly observed that the treatment of FCS and GAL on P. 
aurea resulted in a change in the band intensity at the loading wells (stacking gel) and at the end 
of the resolving gel (MW < 10 kDa). This result suggested that both the enzymes, FCS and GAL 
were most likely to be functioning by cleaving the carbohydrate linkages of P. aurea. Hence, this 
further suggested that the α-fucose and α-galactose linkages in the polysaccharide from P. aurea 
are not important for its immuno-stimulatory activity. As for ISPP-Rb, upon treatment with both 
enzymes, a smear pattern with less visible distinct bands at around or above 250 kDa and around 
45-70 kDa were observed. I reasoned that both enzymes were also active against ISPP-Rb. This is 
because (i) equal amounts of enzymes (FCS and GAL) were added in excess to the polysaccharide, 
(ii) both the polysaccharides had fucose and galactose linkages, and (iii) both the enzymes were 
shown to be active against polysaccharide from P. aurea (Figure 27). Nevertheless, it remains a 
possibility that ISPP-Rb did not have any α-fucose and α-galactose linkages but rather β-fucose 
and β-galactose. This requires confirmation by structural elucidation using NMR analysis. With 
the above rationale, it was concluded that the α-fucose and α-galactose linkages, if truly present in 
ISPP-Rb, are not important for its immuno-stimulatory activity. 
3.22 Glycosidic Bond Analysis of ISPP-Rb 
 Enzyme assays using Proteinase K to digest ISPP-Rb showed that the protein portion of 
the polysaccharide-protein mixture is crucial for the compound’s immuno-stimulatory activity. 
Hence, it is important to know whether there exist covalent interactions (O- or N-glycosidic bond) 
between the protein and polysaccharide. To investigate the possibility of an O-linked bond 
between the polysaccharide and the protein, we used a method called β-elimination assay which 
employs a reducing agent, Sodium Borohydride (NaBH4). The methodology was as described in 
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section 3.10. Figure 28a and 28b illustrate a one-time β-elimination assay performed on P. aurea 
polysaccharide-protein complex with the presence of NaBH4 for 2 hours and 16 hours respectively.  
     
Figure 28. (a) UV spectra (230-300 nm) of P. aurea polysaccharide-protein complex treated/not 
treated with 0.1 M NaOH and NaBH4 for 2 hours; (b) UV spectra (230-300 nm) of P. aurea sample 
treated/not treated with 0.1 M NaOH and NaBH4 for 16 hours Data presented is a representation 
of one single experiment. 
 
 Based on the data from the above optimization step, it can be observed that the pattern 
(trend) and the absorbance values from both times were similar. Hence, the data suggests that 
reaction time can take place any time between 2 – 16 hours without a change in absorbance values. 
With that, subsequent β-elimination assays were conducted using a positive control, aggrecan and 
ISPP-Rb. Figure 29a and Figure 29b illustrate the effect of their UV spectrum upon treatment 
with 0.1 M NaOH and 2 M NaBH4 each for 4 hours. 
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Figure 29. UV spectrum (230-300 nm) of (a) positive control, aggrecan; (b) the polysaccharide 
protein complex of R. badius, ISPP-Rb treated/not treated with 0.1 M NaOH and NaBH4 for 4 
hours. Data presented is a representation of one single experiment. 
 
 Based on Figures 29a-b, it can be noted that the positive control (aggrecan) demonstrated 
an increase in absorbance at 240 nm, while ISPP-Rb showed a decrease in absorbance. Based on 
the results from this experiment, I decided to experiment on another β-elimination assay without 
the use of NaBH4, with the methodology also described in section 3.10. Figures 30a-b illustrate 
the effect of the UV spectrum of the samples upon treatment with 0.1 M NaOH each for 2 hours. 
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Figure 30. UV spectra (230-300 nm) of (a) positive control, aggrecan and (b) polysaccharide 
protein complex of R. badius, ISPP-Rb treated/not treated with 0.1 M NaOH 2 hours. Data 
presented is the mean ± SD from two independent experiments (n=2). Statistical analysis was 
assessed using Multiple Student t-Test with N.S (P > 0.05), *** (P < 0.05) on treated samples 
compared to non-treated samples at their respective wavelengths.  
 
According to Figures 30a-b, it can be concluded that the positive control (aggrecan) was 
valid with an increase in absorbance value at 240 nm. ISPP-Rb also showed a small increase in 
absorbance at 240 nm, suggesting a relatively small amount of O-linked bonds present. On the 
other hand, a purified sample from E. tinctorium sample showed a decrease in absorbance at 240 
nm (data not shown), indicating the absence of any O-linked bonds, and hence was served as a 
negative control in this assay.  
According to O’Neill (1996) and Roth et al. (2012) , the alkaline degradation of the O-
linked polysaccharides with the presence of NaBH4 prevents the degradation of the released 
glycans by reducing the aldehyde ends, which might be necessary for downstream analysis 
purposes on the glycans. However, the use of the reducing agent (NaBH4) was postulated to have 
affected the main compound necessary for the visualization of the increase absorbance at 240nm. 
It was reported that during the β-elimination process, α-aminoacrylic acid and α-aminobutenoic 
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acid are produced as a result of alkaline hydrolysis of the O-linked glycosidic bond attached 
between a serine or threonine group to the glycan, which gives the increased absorbance at 240 
nm (Yi et al., 2011). The use of the reducing agent, NaBH4 was reported to reduce both α-
aminoacrylic acid and α-aminobutenoic acid into alanine and α-aminobutyric acid respectively 
(Wu et al., 2015). Such a reaction could have resulted in the decreased of α-aminoacrylic acid and 
α-aminobutenoic acid, and hence resulting in a less significant increase in the absorbance at 240 
nm. This could be the reason why there was a greater increase in absorbance in the absence of 
NaBH4 (Figure 29a) compared to that of in the presence of NaBH4 (Figure 30a). With the above 
rationale, it is safe to say that the data obtained from the β-elimination in the absence of NaBH4 is 
more reliable, which allows for the conclusion that ISPP-Rb contains a small portion of O-linked 
glycosidic bonds. 
3.23 Cytokine Analysis of ISPP-Rb 
Throughout the entire study of the immuno-stimulatory activity of the compound from the 
water extracts, E3 of R. badius, the validation of its bioactivity was entirely dependent on detection 
of TNF-α produced by RAW 264.7 cells. This suggests that the active compound functions through 
a proinflammatory response. Hence, the supernatants of the ISPP-Rb treated RAW 264.7 cells 
were collected and sent to Eve Technologies to screen for other cytokines/chemokines induced 
using the Mouse Cytokine 32-Plex Discovery Assay. Table 31 shows the cytokines and 
chemokines that were significantly induced by the active compound, while Table 32 depicts the 
abbreviations and full names of the cytokines listed in Table 31. 
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Table 31. Major cytokines and chemokines induced with the treatment of the purified active 
compound, ISPP-Rb. Data presented are from two separate experiments. 
Immune 
Response 
Cytokine 
Replicate 1 Replicate 2 
Blank ISPP-Rb Blank ISPP-Rb 
TH1 TNF-α 2.07 363.25 3.89 445.33 
TH17 
IL-17 <0.10 2.01 <0.10 2.07 
IL-6 <0.67 2.28 <0.67 27.63 
Other 
Chemokines 
IP-10 <0.05 43.51 1.52 87.66 
MIP-2 7.27 1528.48 23.08 5493.2 
G-CSF <0.41 54.62 <0.41 705.67 
GM-CSF <0.77 19.78 0.77 192.76 
IL-1α <1.89 6.46 <1.89 8.41 
1L-1β 4.96 8.94 1.88 5.4 
LIF <0.17 8.19 <0.17 32.97 
MIP-1α 108.71 6564.67 340.68 6463.46 
MIP-1β 96.1 35133.11 337.21 177428.68 
RANTES <0.60 3.43 <0.60 6.29 
 
Table 32. Major cytokines and chemokines induced with the treatment of the purified active 
compound, ISPP-Rb.  
Abbreviation Full Name 
TNF-α Tumor-Necrosis Factor 
IL-17 Interleukin-17 
IL-6 Interleukin-6 
IP-10 Interferon Gamma-Induced Protein 10 
MIP-2 Macrophage Inflammatory Protein 2 
G-CSF Granulocyte-Colony Stimulating Factor 
GM-CSF Granulocyte Macrophage-Colony Stimulating Factor 
IL-1α Interleukin-1α 
1L-1β Interleukin-1β 
LIF Leukemia Inhibitory Factor 
MIP-1α Macrophage Inflammatory Protein 1α 
MIP-1β Macrophage Inflammatory Protein 1β 
RANTES N/A 
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Based on Table 31, it can be seen that the major cytokines induced by ISPP-Rb were 
mainly proinflammatory such as are TNF-α, IP-10, MIP-2, G-CSF, GM-CSF, MIP-1α, and MIP-
1β. The data shows that the active compound mainly stimulates the TH1 and/or TH17 response. 
Because the cells were treated with an unknown dose of the bioactive compound directly eluted 
from the Hi Prep Sephacryl S500 column, the average values were not able to be estimated and 
hence are presented as two separate experimental data. 
3.24 Effect of ISPP-Rb on the Phagocytic Activity of RAW 264.7 Cells 
With the cytokine data depicting the induction of proinflammatory response, it was decided 
to see if the bioactive compound would be able to results in cell phagocytosis. The optimization 
protocols are as described in section 3.12. Initial results suggested that the assay should be carried 
out in DMEM without FBS due to the fact the FBS resulted in untreated RAW 264.7 cells to 
continue to proliferate. Such a phenomenon resulted in an increase in cell density in control wells 
compared to those treated with LPS (data not shown), making the experimental condition of the 
controls different from the treated group. The subsequent experiments were resumed using DMEM 
without FBS as the media of choice, however, due to inconsistencies obtained from the absorbance 
reading after several trials, the experiment was abandoned. 
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Chapter 4 
General Discussion and Future Directions 
This chapter aims to compare and contrast the immuno-stimulatory polysaccharide-protein 
complex isolated from Royoporus badius (ISPP-Rb) with immuno-stimulatory mushroom 
polysaccharide/polysaccharide-protein complex reported in the literature. Recommendations and 
suggestions will also be given to further improve the future execution of this research study. 
4.1 Bioactivity Studies on the Mushroom Genus Royoporus 
 To the best of my knowledge, there are currently only 3 species categorized in the genus 
Royoporus, namely Royoporus badius, Royoporus spathulatus (Jungh.) De and Royoporus 
pseudobetulinus (Murashk. Ex Pilát) A.B. De (Doskocil et al., 2016; Karun & Sridhar, 2017; 
Sotome et al., 2011). However, out of the three species, only R. badius has been studied for its 
bioactivity, but with very limited information available. One study showed that the ethanol extract 
of R. badius exhibited little cytotoxic activity towards colorectal cancer cell lines and had some 
phenolics present in the extract (Doskocil et al., 2016). Elsewhere, the ethanol extracts of R. badius 
successfully inhibited the production of proinflammatory cytokines but elicited TH2 response 
(Koch et al., 2002). In the two studies, there were no reports on possible compounds responsible 
for the bioactivity. The general lack of bioactivity studies described for the genus Royoporus, and 
the absence of any report on immuno-stimulatory compound from R. badius lends support for the 
novelty of the research described in my study. 
4.2 General Project Overview 
 The crude extracts of mushroom R. badius was initially screened for immuno-stimulatory 
activity by an undergraduate student (Mr. Jatinder Khatra) in Dr. Lee’s lab, and it was discovered 
that the water extract E3 of the polypore exhibited potent immuno-stimulatory activity on mouse 
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macrophage RAW 264.7 cells. With that initial finding, I started my research study on R. badius, 
which involved purifying and characterizing the immuno-stimulatory compound from E3 of the 
mushroom. LH20 SephadexTM size-exclusion chromatography was first used in the purification 
step. Based on the elution volume from LH20 SephadexTM, the bioactive compound was predicted 
to be relatively large and was subjected to purification using DEAE SephadexTM anion-exchange 
chromatography, followed by a high-resolution size-exclusion chromatography (SEC) using 
Sephacryl S500 as the second purification step (Chapter 2). The purified immuno-stimulatory 
compound, ISPP-Rb was then subjected to various biological and chemical characterization 
(Chapter 3). 
4.3 Purification of the Water Extract E3 from R. badius 
4.3.1 Using LH20 SephadexTM to Purify the Water Extract E3 from R. badius 
 LH20 SephadexTM is a separation matrix used in SEC, with an exclusion limit of 
approximately 4-5 kDa. The water extract E3 of R. badius, when subjected to the LH20 
SephadexTM column, eluted the immuno-stimulatory compound at an early elution volume, 
suggesting that the immuno-stimulatory compound is relatively large. Carbohydrate analysis using 
the Phenol-Sulphuric assay showed that the compound was likely to be a polysaccharide. The 
estimated large size of the immuno-stimulatory compound and the possibility of it being a 
polysaccharide suggested that LH20 SephadexTM might not be a suitable separation matrix for the 
purification of the immuno-stimulatory compound. 
4.3.2 Using DEAE SephadexTM A-50 to Purify the Water Extract E3 from R. badius 
 Various amine buffers were assessed for possible use as the buffer system with DEAE 
SephadexTM A-50 purification. All 6 buffers, Piperazine (pH 5.33), Bis Tris (pH 6.48), water (pH 
7.00), Triethanolamine (pH 7.76), Propane-1,2-Diamino (pH 8.88) and Ethanolamine (pH 9.50) 
were shown to be suitable for the elution of the immuno-stimulatory compound using 1 M NaCl 
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dissolved in their respective buffers (see Figure 6). Such a phenomenon can be explained by the 
fact that the immuno-stimulatory compound is likely to have an isoelectric point (pI) lower than 
pH 5.33. Amongst all buffers experimented, Bis Tris (pH 6.48) was selected based on the fact that 
it took little time to equilibrate. Despite water being widely used in DEAE purification of 
polysaccharides (Chen et al., 2017; Yuan et al., 2015), the immuno-stimulatory compound eluted 
from the water-buffered DEAE column gave the least immuno-stimulatory activity as compared 
to the buffer systems experimented (see Figure 6). The fact that water being a poor buffer would 
result in the possibility of pH fluctuations occurring during column runs; hence, water was not 
used for DEAE purification. 
 One of the major advantages offered by DEAE as the first purification step was the matrix’s 
high loading capacity as compared to SEC. The loading capacity of size-exclusion columns are 
restricted by the matrix’s loading capacity which results in less amount being able to be loaded per 
column run. Challenges encountered in DEAE are the long column run hours and the need to rota-
evaporate and dialyze eluted fractions containing high amounts of salt. 
4.3.3 Using Hi-Prep Sephacryl S500 to Purify the Water Extract E3 from R. badius 
 SEC, otherwise known as gel-permeation chromatography equipped with detection system 
units is by far the most technologically advanced and easily accessible equipment available for 
proper separation and size estimation of polysaccharides (Vilaplana & Gilbert, 2010). The Hi-Prep 
Sephacryl S500 is a high-resolution SEC with a separation capacity of 40-2000 kDa and was used 
as the second step purification. The buffer solution used was degassed 150 mM NaCl in MilliQ 
water to reduce interaction between the compound(s) with the matrix of the column. The fractions 
were collected and assessed for immuno-stimulatory activity on RAW 264.7 cells. Active fractions 
were then pooled, dialyzed, lyophilized and named ISPP-Rb.  
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Prior to pooling the active fractions, each individual fraction was also assessed for their 
respective carbohydrate and protein contents. Despite the presence of both carbohydrates and 
protein detected in the peak active fraction, the carbohydrate and protein peak were detected later 
in the subsequent fractions (see Figure 18a-b). This suggested the possibility that unwanted 
carbohydrates and proteins were co-eluted with the immuno-stimulatory compound. The use of 
HPLC will allow for purity confirmation using the refractive index detector (RID). Based on 
Sephacryl S500, the size of the immuno-stimulatory compound was estimated to be approximately 
400 kDa using dextran standards (see Figure 19).  
 The advantage of using the Hi-Prep Sephacryl S500 was that the column was equipped 
with the ÄKTA FPLC System allowing visualization of the chromatogram. Furthermore, the 
preparative column allowed for an increase in loading capacity, which is often limited in size-
exclusion columns and analytical columns. 
4.4 Characterization of the Water Extract E3 from R. badius 
4.4.1 Chemical Composition of ISPP-Rb 
Carbohydrate and protein analysis using GC-MS and BCA assay showed that ISPP-Rb 
contained 57.4% carbohydrate and 16.7% protein, with the remaining 25.9% still unknown. A 
similar pattern was observed elsewhere in the literature (Chen et al., 2008), whereby a 
polysaccharide (AAP) extracted from Auricularia auricula (Bull.) J.Schröt. was reported to 
contain 42.5% of carbohydrate, 19.6% uronic acids, with the remaining made up of sulfate groups, 
nitrogen, and ash. Hence, it is possible that the unknown 25.9% of ISPP-Rb are a mixture of other 
inorganic components.  
β-glucans are naturally occurring heterogenous polysaccharides. The immuno-stimulatory 
effect of mushroom β-glucans have been extensively reported, which includes but is not limited to 
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β-glucans from L. edodes, Schizophyllum commune Fries, and Sclerotium glucanicum Halleck 
(Kim et al., 2011). This led to the interest in investigating the carbohydrate portion of ISPP-Rb for 
the presence of β-glucans. However, it was discovered that ISPP-Rb contain none or very little 
amount of β-glucan, which is surprising due to the fact that the production of β-glucans are mainly 
found in fungi as compared to seaweeds, bacteria and cereal (Novak & Vetvicka, 2008). The results 
were interesting considering that not only are β-glucans found naturally in fungi, but also due to 
the presence of approximately 40% of glucose monosaccharides detected using GC-FID analysis 
on ISPP-Rb. However, it eventually became clear upon the results from GC-MS analysis; these 
results showed that the source of the glucose monosaccharides was derived from the presence of 
terminal glucose and (1 → 2,6)-Glc linkages in ISPP-Rb. In addition, the absence of (1 → 3)- 
and/or (1 → 6)-Glc linkages further confirm the absence or extremely low amount of β-glucan in 
ISPP-Rb. 
The preliminary monosaccharide content data from GC-FID showed that ISPP-Rb were 
made up mainly of galactose (45.8%) and glucose (39.8%), with only 10% of mannose and less 
than 5% each of xylose and fucose (see Table 29). The data was consistent with the linkage 
analysis from GC-MS (see Table 30), with glucose and galactose linkages accounting for the 
majority of all the carbohydrate linkages. The backbone of the polysaccharide contains a linkage 
mixture of (1 → 6)-Gal (13.0%) and (1 → 6)-Man (16.3%), with a branching point of (1 → 2, 6)-
Glc (39.7%) having unsubstituted, fucose (8.2%), glucose (6.0%) and galactose (16.8%). However, 
xylose linkages were not detected, which is likely due to the low amounts (1.3%) present. The 
carbohydrate linkage analysis data showed that ISPP-Rb is a highly branched polysaccharide, with 
a degree of branching (DB) of 0.71. The high level of branching originated from the presence of 
the branching point at (1 → 2,6)-Glc. To the best of my knowledge,  only one immuno-modulatory 
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proteoglycan containing such a linkage was only reported. Ye et al. (2011) reported an immuno-
regulative proteoglycan extracted from the fruiting body of G. lucidum, capable of enhancing the 
proliferation of mouse spleen lymphocyte resulting in the activation of B-cells. Elsewhere, the (1 
→ 2,6)-Glc linkage was also reported but not for the compounds with immuno-modulatory 
activities.  Pan et al. (2012) identified a neutral polysaccharide with anti-hyperglycemic activity 
isolated from G. lucidum, while Scarpari et al. (2017) reported a possible polysaccharide 
containing such a linkage with pro-antioxidant properties. Table 33 provides a literature list of 
some non-β-glucan immuno-modulatory mushroom polysaccharide/polysaccharide-protein 
complexes along with their carbohydrate linkages. 
Table 33. Carbohydrate linkages of some non-β-glucan immuno-modulatory mushroom 
polysaccharide/polysaccharide-protein complexes. 
Mushroom Active Compound Carbohydrate Linkages Reference 
Phellinus 
igniarius (L.: 
Fr) Quel 
Polysaccharide 
(PPIP60-1) 
 
Backbone consists of (1 → 6)-
Gal, (1 → 2,6)-Gal, (1 → 2,4)-Gal, 
(1 → 2,6)-Man; 
 
Side Chain consists of terminal 
glucose and fucose 
 
(Yang et al., 
2007) 
Polysaccharide (PISP1) Backbone consisting of (1 → 6)-
Gal, (1 → 3,6)-Man, (1 → 4)-Gal, 
and (1 → 2)-Gal; 
 
Side Chain contains terminal 
fucose 
 
(Yang et al., 
2009) 
Polyporus 
rhinocerus 
Polysaccharide-Protein 
Complex (PRW1) 
Backbone consist (1 → 4)-Glc, (1 
→ 6)-Glc and (1 → 2)-Man; 
 
Branching/Side chains were (1 
→ 3,6)-Glc, (1, → 4,6)-Glc and of 
terminal glucose 
 
(Liu et al., 
2016) 
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 Polysaccharide (PRW) Backbone consist of (1 → 2)-
Man, (1 → 6)-Glc, and (1 → 4)-
Glc; 
 
Branching/Side Chains consists 
of terminal glucose, (1 → 3,6)-
Glc and (1 → 4,6)-Glc 
 
(Liu et al., 
2018) 
Ganoderma 
lucidum 
Proteoglycan  
(LZ-D-7) 
Backbone consists of (1 → 4)-
Glc, and (1 → 2,6)-Glc; 
 
Side Chain consists of terminal 
glucose 
 
(Ye et al., 
2011) 
 Polysaccharide (FMS) 
 
Backbone consists of (1 → 4)-
Man and α-(1 → 6)-Gal; 
 
Side Chains consists of terminal 
fucose attached to (1 → 2)-Gal, 
(1 → 3/4)-Man, (1 → 4)-Xyl, and 
(1 → 2)-Fuc 
 
(Liao et al., 
2013) 
Hypsizygus 
marmoreus 
(Peck) H.E. 
Bigelow 
Proteoglycan (F1) 
Proteoglycan (F2) 
Backbone consists of α-(1 → 3)-
Glc, α-(1 → 4)-Glc, and β-(1 → 
6)-Glc; 
 
Branching Chain consists of (1 
→ 3,6)-Glc, (1 → 4,6)-Glc, and 
terminal glucose 
 
(Bao et al., 
2012) 
Flammulina 
velutipes 
Polysaccharide 
(FVPB2) 
Backbone consists of α-(1 → 2)-
Gal, and α-(1 → 6)-Glc; 
 
Branching Chain consists of (1 
→ 3,6)-Glc, (1 → 3,4)-Gal linked 
with terminal fucose and 
mannose respectively 
 
(Wang et al., 
2018) 
 
Based on Table 33, and to the best of my knowledge, there have not been reports of an 
immuno-stimulatory mushroom compound containing terminal galactose. Common terminal 
sugars found are either glucose or fucose. According to the GC-MS data obtained, ISPP-Rb 
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contained 16.8% of terminal galactose, along with 8.2 % and 6.0 % of terminal fucose and terminal 
glucose respectively. Other than that, ISPP-Rb is by far the second immuno-stimulatory mushroom 
molecule that contains the (1 → 2,6)-Glc linkage. Taken together, this could prove that ISPP-Rb 
is indeed a unique and novel immuno-stimulatory compound. 
Reports on mushroom polysaccharides (mainly β-glucans) with high degree of branching 
exhibiting immuno-modulatory activity are rare. A hyper-branched β-glucans (mPRSon) with a 
DB of 0.85 was purified from the sclerotia of P. rhinocerus and was shown to exhibit immuno-
modulatory activity (Liu et al., 2018). Elsewhere, a water-soluble β-glucan (TM3b) isolated from 
Pleurotus tuber‐rigium (Rumph. ex Fr.) Singer was found to be extensively branched (DB = 0.58). 
However, the bioactivity of the polysaccharide was not described (Tao & Zhang, 2006). On the 
other hand, mushroom polysaccharides (β-glucan) with lower degree of branching (DB ≤ 0.50) 
reported are pachymaran, lentinan, pleuran, grifolan, scleroglucan, schizophyllan, and SSG 
(Novak & Vetvicka, 2008). The only mushroom non-β-glucan, i.e. mushroom polysaccharide-
protein complex with a high degree of branching reported was PRW, which was isolated from the 
sclerotia of P. rhinocerus, having a DB of 0.60 and exhibiting potent immuno-stimulatory activity 
(Liu et al., 2016). From the literature, it is clear that most of the immuno-modulatory 
polysaccharides are β-glucan, with very limited polysaccharide-protein complexes being immuno-
stimulatory. Hence, the fact that ISPP-Rb is suggested to be a non-β-glucan polysaccharide-protein 
complex containing a high DB of 0.71, suggests that it is a novel immuno-stimulatory compound. 
4.4.2 Enzyme Degradation Assay on the Immuno-Stimulatory Activity of ISPP-Rb 
Experiments were designed to further understand the significance of the carbohydrate 
and/or protein portion of the purified polysaccharide-protein complex in contributing to the 
immuno-stimulatory activity. The basis of this study was to treat the active compound with specific 
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enzymes and see whether its immuno-stimulatory activity is reduced. Any decrease in immuno-
stimulatory activity would suggest the importance of the digested portion (polysaccharide and/or 
protein) of the compound. Based on the data obtained from section 3.21, I concluded that the 
protein portion of ISPP-Rb was important for its immuno-stimulatory activity. The treatment of 
Proteinase K (1 mg/mL) on ISPP-Rb (1.5 mg/mL) for 2 hours at 37°C completely abolished the 
immuno-stimulatory activity of the compound (see Figure 23), indicating that the protein 
component is indispensable for its immuno-stimulatory activity.  
Enzymes that cleave carbohydrate linkages such as α-amyloglucosidase (AMG), α-L-
Fucosidase (FCS) and α-Galactosidase (GAL) were also used in the enzyme degradation assay. 
AMG was selected during the first phase, when the carbohydrate linkage analysis was still 
unknown. The rationale was the suspicion that the immuno-stimulatory activity of ISPP-Rb was 
due to the presence of glucans and the fact that AMG is capable of hydrolyzing α-1,3-, α-1,4-, and 
α-1,6-glucosidic bonds. The use of GAL was because the galactose-linkages (excluding 1,2,6-
Glucose) and monosaccharide content were the highest, and it was thought that the high amount 
of galactose would play a role in the active compound’s immuno-stimulatory activity. The use of 
FCS was based on study reporting that mice immunized with fucose-rich polysaccharides extracted 
from G. lucidum had induced antibodies against Lewis lung carcinoma cells (Liao et al., 2013). 
However, based on the overall data obtained (see Figures 22, 24-26), it was suggested that the 
carbohydrate portion of ISPP-Rb may not be important for its immuno-stimulatory activity. 
To the best of my knowledge, this experiment was the first of its kind as there have been 
no reports in the literature citing the use of enzymes as an indirect method in assessing the 
importance of the protein and polysaccharide components in bioactive compounds derived from 
mushrooms. The advantage of this experiment is the relatively short time required, which includes 
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enzyme treatment followed by cell-based experiment. However, this assay proved difficult due to 
the lack of suitable positive controls, i.e. polysaccharide/polysaccharide-protein complex with 
immuno-stimulatory activity. This is because of the differences in carbohydrate and/or protein 
linkages present in each individual compound. Issues were encountered during the treatment of 
FCS and GAL on the polysaccharide isolated from P. aurea (positive control) and ISPP-Rb, where 
neither the positive control nor ISPP-Rb showed a change in immuno-stimulatory activity after 
being treated with FCS and GAL (see Figures 24-26). The solution to this was by running the 
polysaccharide samples treated/not treated with enzymes FCS and GAL on a SDS PAGE gel, 
which were then visualized using a glycoprotein staining kit to observe any changes in band/smear 
patterns (see Figure 27). 
4.4.3 Helical Confirmation of ISPP-Rb using Congo Red Assay 
The Congo red assays allow for the visualization of the presence of a triple helix structure 
via an observation of a shift in the maximum absorption of the polysaccharide-Congo red complex 
as compared to the Congo Red solution (blank) when treated with mild NaOH solution (Smiderle 
et al., 2014). Ogawa et al. (1972) reported that β-1,3- and β-1,4- glucans will form a complex with 
Congo red under diluted NaOH conditions. This was consistent with studies involving the use of 
β-glucans, with α-glucans failing to form the complex with Congo red (Palacios et al., 2012; Wang 
et al., 2013). Surprisingly, despite P. aurea polysaccharide containing significant β-glucans (see 
Table 28), it failed to bind with Congo red, as indicated by the absence in shift in the maximum 
absorption (see Figure 20b). This phenomenon could be explained by the presence of a protein 
component on P. aurea polysaccharide, which could have hindered the binding process, as was 
observed with PSK, which is a protein bound β-1,3- and 1,6-glucan but failed to show any shift in 
maximum absorbance. It was explained that despite both PSK and PSP containing β-glucans, the 
108 
 
presence of  a protein molecule attached to the glucan makes them different from pure β-glucans  
(Chan et al., 2009). The same situation was observed for ISPP-Rb, which also contain a protein 
portion. Therefore, without a suitable positive control, the results from these experiments remained 
inconclusive.  
4.4.4 Glycosidic Linkages of ISPP-Rb 
The β-elimination assay carried out in the absence of the reducing agent, NaBH4 suggested 
that there is a small amount of O-linked glycosidic bond present in ISPP-Rb. However, statistical 
analysis showed that the difference observed was not significant. Despite this, the presence of the 
O-linked glycosidic bond could indeed be biologically significant and should not be assumed as 
absent. It is important to point out that fungal glycoproteins containing fucosylated O-glycans 
(mainly O-mannans), despite being rare, have been reported in chanterelles and Boletus edulis 
(Grass et al., 2011). This further supports the possible presence of the O-linked glycosidic bond in 
ISPP-Rb and the likelihood that fucosylated O-linked mannans is present in ISPP-Rb. 
4.4.5 Cytokine, Chemokine and Phagocytosis Induction in RAW 264.7 Cells by ISPP-Rb 
 ISPP-Rb was found to mainly induced proinflammatory responses by stimulating the 
production of TNF-α, IP-10, MIP-2, G-CSF, GM-CSF, MIP-1α, and MIP-1β. The data shows that 
the active compound mainly stimulates the TH1 and/or TH17 response, which led to the rationale 
that ISPP-Rb would be able to induce phagocytosis in RAW 264.7 cells. Unfortunately, the Neutral 
Red assay which was designed to visualize macrophage phagocytosis through colorimetry 
observations were inconsistent and irreproducible. The use of 96-well plates in this experiment 
increases the chances of error due to the multiple pipetting steps involved. It is thought that with 
every pipetting step, the adherent cells were disturbed resulting in the fluctuation of cell densities 
across the wells, which could explain the irreproducible results. A more reliable but much more 
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sophisticated assay to measure phagocytic activity in RAW 264.7 cells will be to use the flow 
cytometer. Several studies using the flow cytometer to study macrophage phagocytosis involved 
the use of biodegradable microspheres/latex beads conjugated to a fluorescence label, fluorescein 
isothiocyanate (FITC) (Im et al., 2010; Razali et al., 2014).  
4.5 Proposed Structure for ISPP-Rb 
 Based on the carbohydrate linkages obtained from GC-MS, the possible presence of the O-
linked glycosidic bond, and information from the literature, I proposed a general structure of ISPP-
Rb as shown in Figure 31. 
 
Figure 31. A proposed structure of the polysaccharide component of ISPP-Rb. Fucp, Galp, Glcp, 
and Manp represents fucose-pyranose, galactose-pyranose, glucose-pyranose, and mannose-
pyranose respectively. 
 
ISPP-Rb contain similar amounts of (1 → 6)-Man and (1 → 6)-Gal linkages, with each 
accounting for 16.3% and 13.0% respectively. On the other hand, the (1 → 2,6)-Glc linkage was 
2-3 times more abundant compared to the prior. With that data, it is very likely that there should 
be near equal amounts of (1 → 6)-Man and (1 → 6)-Gal linkages, with the (1 → 2,6)-Glc linkage 
being at least twice as much as compared to the previous two. The presence of terminal fucose, 
glucose and galactose would suggest that they will be linked by a Fuc/Gal/Glc-(1 → 2)-Glc linkage. 
In this study, I reported the importance of the protein component for the immuno-stimulatory 
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activity of ISPP-Rb. It is suggested that the protein component of ISPP-Rb is being O-linked to 
the mannose sugar of the polysaccharide. This is because mannoproteins are commonly found in 
the cell walls of fungi (Klis et al., 2006), with O-mannans being reported to be found in 
chanterelles and Boletus edulis (Grass et al., 2011). In addition, an immuno-stimulatory 
polysaccharide-protein complex linked to a mannose residue have been previously reported (Liu 
et al., 2016). To confirm the structure of ISPP-Rb, high resolution NMR studies will be required. 
4.6 Conclusion and Future Directions 
 An immuno-stimulatory polysaccharide-protein complex was successfully purified from 
the water extract E3 of R. badius and was named ISPP-Rb. The immuno-stimulatory compound is 
water soluble and has a molecular weight of approximately 400 kDa. The active compound is 
relatively heat stable and definitely requires the protein portion for its immuno-stimulatory activity. 
Further detailed studies are needed to determine whether the polysaccharide portion of ISPP-Rb is 
critical for its immuno-stimulatory activity. ISPP-Rb has a highly branched polysaccharide and 
likely linked to its protein component at least through O-glycosidic bonds. ISPP-Rb induces 
proinflammatory cytokines and chemokines. This is the first study to report on a large immuno-
stimulatory polysaccharide-protein complex isolated from the mushroom R. badius. 
 The chemical characterization studies conducted on ISPP-Rb is still only preliminary and 
requires further investigation. HPLC is required to check for purity of the isolated compound. The 
pure sample should be sent for high-resolution NMR analysis to elucidate the structure of its 
polysaccharide component. N-glycosidase enzyme PNGase F could be used to determine the 
possible presence of N-linked glycosidic bond. If N-linked glycosidic bonds are present and the 
protein component is released and detected on a SDS-PAGE gel upon PNGase F treatment, the 
protein gel slice could be sent for N-terminus amino acid sequencing analysis. With the N-terminus 
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amino acid sequence information, the identity of the active protein molecule, if any, could be 
determined using the National Center for Biotechnology Information (NCBI) database. 
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